2025
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Lifetech SCIENTIFIC

LifeTech Scientific Corporation
先 健 科 技 公 司

(Incorporated in the Cayman Islands with limited liability)
Stock Code: 01302

CONTENTS

Dear stakeholders,

On behalf of the board (the "Board") of directors (collectively, the "Directors", and each a "Director") of LifeTech Scientific Corporation (the "Company" or "LifeTech"), I am pleased to present the Environmental, Social and Governance ("ESG") report (the "Report") of the Company and its subsidiaries (collectively the "Group" or "we") for the year ended 31 December 2025.

Sustained Business Growth, Numerous Research & Development Breakthroughs

In 2025, the Company steadily advanced in a complex and ever-changing market environment, continuously consolidating its leading position in the domestic market while accelerating its expansion into international markets. Domestically, it further strengthened its market foundation through broader adoption of its innovative product portfolio. Internationally, it earned wider recognition, achieving sustained and considerable growth in overseas revenue.

In the field of research and development, multiple products have obtained registration approval and been successfully launched in the market. Meanwhile, certain products have progressed to the registration or clinical stage both domestically and internationally. The Aortic Stent Graft System, Aortic Arch Stent Graft System, and Thoracoabdominal Artery Stent Graft System—three independently developed innovative products—all successfully obtained the National Medical Products Administration ("NMPA") certification. Meanwhile, the IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System successfully completed the three-year follow-up of its phase II clinical study and two-year follow-up of the phase III clinical studies, with primary endpoint follow-up results announced, further enhancing the evidence-based medical foundation for this innovative product. Furthermore, the Congenital Heart Defect Occluder was admitted into the NMPA Special Examination and Approval Procedure for Innovative Medical Devices, marking the 16th product of the Company to receive this recognition.

In 2025, our innovative interventional treatment technologies continued to receive industry recognition. The project "Development and Domestic and International Promotion of Innovative Endovascular Devices" was awarded the First Prize of the Chinese Medical Science and Technology Award by the Chinese Medical Association. The Company was also honored with the "Global Cardiovascular Clinical Application Award" at the inaugural Global Cardiovascular Conference 2025. Additionally, the project "Promotion and Application of Key Technologies and Products for pediatric congenital heart disease interventional treatment" was honored with the Guangdong Provincial Science and Technology Achievement Promotion Award. These achievements not only affirm our past efforts, but also highlight our leading position and innovative capabilities in the industry, inspiring us to continue advancing and breaking new ground in the medical field through technological innovation.

Improving Product Quality, Seeking Global Opportunities

Looking ahead, the Group will continue to steadfastly advance its dual-driven strategy of innovation and internationalization. We will persistently promote the development and translation of innovative products, drive breakthroughs in key technologies and product iterations, and actively accelerate the application of new technologies and therapies. By continuously optimizing our product portfolio and total solutions, we aim to address ever-evolving clinical needs and steadily enhance our market competitiveness. As the global population aging trend intensifies, medical technology continues to advance, and healthcare demand keeps rising, the medical device

industry is expected to maintain long-term growth potential. Although the ongoing implementation of centralized procurement policies in China has brought certain pricing pressures on some medical device products, it has also accelerated industry consolidation, driving enterprises to transform and upgrade towards high value-added, differentiated, and innovation-driven directions. This presents greater development opportunities for companies with systematic innovation capabilities.

In 2026, we will further strengthen our global operational management capabilities and accelerate the commercialization of innovative products. Through the continuous refinement of our distribution network, we will drive deeper market penetration of our innovative products worldwide and actively expand our international business. We firmly believe that, with our solid innovation capabilities, robust industrial foundation, and continuously deepening global presence, we will be well-positioned to capture opportunities and navigate challenges in a complex and ever-changing market environment. By working hand in hand with all stakeholders, we will continue to advance medical technology, create long-term value for our patients, healthcare institutions, and shareholders, and make meaningful contributions to global health.

Acknowledgement

On behalf of the Board, I would like to express my sincere gratitude for the continued support from our stakeholders and their valuable feedback, pushing forward the Group's sustainability journey. Also, I thank our employees' dedicated efforts for excellence and success, driving the Group to provide quality products, attain accomplishment in research, development and innovation, as well as maintain the Group's sustained growth. Their unwavering support and dedication have enabled the Group to forge ahead and grow stronger in this challenging period. After years of development, China has become the second largest medical device market in the world. In terms of development space, the total industrial output value and sales of the medical device industry in China are expected to maintain a steady growth. Based on our solid foundation and our efforts in sustainable development, we will strive to explore new opportunities to achieve sustainable business development and create value for all stakeholders.

XIE Yuehui
Chairman

LifeTech Scientific Corporation

The Report is the tenth *Environmental, Social and Governance (ESG) Report* issued by LifeTech since 2016. It continues to disclose the Group's ESG policies, measures and performance, and provides an important reference for stakeholders to understand the Group's direction, strategy and progress on sustainability matters. The Report is compiled in both Chinese and English, and has been uploaded to the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (www.hkexnews.hk) and the Group's website (www.lifetechmed.com). In the event of any discrepancy, the Chinese version shall prevail.

The Group values the opinions of our stakeholders. If you have any questions or suggestions about the Report, please feel free to contact the Group through the following methods:

Place of business in Hong Kong: 31/F, 148 Electric Road, North Point, Hong Kong

Correspondence address: LifeTech Scientific Building, No. 22, Keji 12th Road South, Nanshan District, Shenzhen

Post code: 518063

Tel.: +86-755-86026250

Email: ir@lifetechmed.com

Reporting Standard

The Report is prepared by the Group in accordance with the *Environmental, Social and Governance Reporting Code* (the "Code") set out in Appendix C2 to the *Rules Governing the Listing of Securities on the Stock Exchange* (the "Listing Rules"), and with further reference to the International Sustainability Standards Board (ISSB)'s *IFRS S1 General Requirements for Disclosure of Sustainability-related Financial Information* and *IFRS S2 Climate-related Disclosures*.

Reporting Principles

The Report follows the four major reporting principles of the *Code* - materiality, quantitative, balance and consistency, and we have taken them as the important basis for preparing the Report.

Materiality	LifeTech has maintained active and effective communication with stakeholders to understand and identify whether or how the Group's major business, operating conditions and sustainable development strategies have been affected. We also continuously pay attention to the performance and challenges of ESG which are significant to the Group and its stakeholders, and authorise partners and engage professional consultants to help the Company organise a stakeholder survey on ESG issues to understand the importance of sustainability to our operations and stakeholders.
Quantitative	The Group has compiled all specific key performance indicator (KPI) data and reference calculation methods in accordance with the Stock Exchange's *How to Prepare an ESG Report*, *Appendix 2: Reporting Guidance on Environmental KPIs* and *Appendix 3: Reporting Guidance on Social KPIs*, and has disclosed the sources of conversion factors used in such calculations.

Balance	The Report impartially discloses the Group's performance during the Reporting Period. It uses appropriate reporting formats, images and charts to present the Group's performance to avoid misleading or affecting the readers' decisions or judgments.
Consistency	The Group confirms that the Report is prepared in the same way as in previous years. We use consistent methodologies to summarise the environmental and social performance of 2025 from its official documents, statistics, as well as management and operation data collected in accordance with its policy.

Reporting Scope and Period

The Report discloses the Group's sustainability performance for the year from 1 January 2025 to 31 December 2025 (the "Reporting Period"), and covers the Group's main business, namely the development, manufacturing and trading of medical devices. During the year, the Company operated production facilities in China, and the reporting scope focuses on the Group's principal place of business and headquarters located in High-tech Industrial Park, Nanshan District, Shenzhen as well as the principal place of business in Songshan Lake Park, Dongguan. In addition, the employment section of the Report includes disclosures related to overseas operating locations.

Board Statement

The Board is the Group's highest responsible and decision-making body for ESG matters. It bears the ultimate responsibility for ESG strategies and reporting, and monitors the ESG matters that may affect the Company's business or operation, shareholders and other stakeholders. The Board regularly reviews the Group's sustainability performance and annual ESG report, identifies ESG and climate-related risks, and ensures these are incorporated into the Group's strategy and major decisions. The Board has appointed an Environmental, Social and Governance Committee (the "ESG Committee") to provide key support to the Board's decision-making and to ensure effective implementation of the Group's ESG strategy.

The Board places great importance on stakeholders' expectations and continuously engages with stakeholders to complete materiality assessments, refine ESG strategies and policies, and set ESG management targets. The Board reviews the results of the materiality assessment on an annual basis, monitors target progress and considers any necessary adjustments or improvements to ensure we continuously optimise our ESG performance.

The Board and the Directors hereby warrant that there are no false records, misleading statements or material omissions contained in the Report and they will take liabilities for the authenticity, accuracy and completeness of the contents herein. The Report provides detailed information on the progress and effectiveness of the Group's ESG work in 2025 and was approved by the Board on 31 March 2026.

ESG Governance Structure

The Group's ESG governance structure consists of the Board, the Environmental, Social and Governance Committee (the "ESG Committee") under the Board and the ESG Taskforce, which is responsible for the overall oversight of the Group's ESG practices and initiatives. To align with the expectations and requirements of regulators, the Group keeps abreast of national and international sustainable development and policy trends and maintains a timely and effective feedback mechanism to incorporate relevant standards and requirements into the ESG governance system.

The Chairman of our ESG Committee is Mr. XIE Yuehui (Chairman and Chief Executive Officer), and he oversees the ESG-related matters on behalf of the Board. The ESG Committee is comprised of senior management members appointed by the Board and serves as the central coordinating body for ESG matters across all departments and operations.

Board	• To decide major ESG-related matters of the Group and monitor the progress and effectiveness of major ESG matters, including identification and response to ESG and climate risks, implementation of ESG optimisation, disclosure of ESG and climate-related information, and communication with stakeholders; • To decide on and monitor the development and update of the Group's ESG and climate-related policies and strategies; • To decide on and monitor the development and update of the Group's overall ESG and climate goals; • To assess and determine the nature and extent of risks that the Group is willing to accept in achieving strategic objectives, and establish and maintain appropriate and effective risk management and internal control systems; • To review the performance indicators on a regular basis and discuss the effectiveness of the ESG program with the ESG Committee.

ESG Committee	• To review, confirm and evaluate the Group's ESG standards, priorities and targets, such as identifying key ESG issues, setting emission control targets, resource and waste utilisation targets, etc.; • To monitor, review and evaluate the actions we take to advance our ESG and climate priorities and targets, including coordination with the Company's business departments, for example working with relevant professional departments to establish sustainable production lines and develop environmentally friendly products, and ensure that our operations and practices are aligned with the relevant priorities and targets; • To monitor and review emerging sustainability issues, as well as national and international standards trends that may affect the Group's business operations and performance, such as major international ESG trends in legislation, regulation, litigation and public opinion; • To monitor and evaluate the impact of our ESG performance on our stakeholders, manage climate-related risks and opportunities, and propose corrective action plans when necessary; • To review, evaluate, advise and lead the preparation of the Group's public communications, disclosures and publications on ESG and climate matters (including but not limited to the disclosure of ESG Report in the Company's Annual Report), maintain the integrity of the Report and ensure compliance with relevant disclosure requirements on ESG matters; • To develop, monitor and review the Group's overall climate-related strategies and approaches; • To report the ESG work results to the Board on a regular basis.
ESG Taskforce	• To execute the Group's ESG and climate policies and strategies, and implement the management and optimisation requirements for related ESG and climate matters within each department; • To report the ESG work results to the ESG Committee on a regular basis.

The Group has established an ESG governance system comprising the Board, the ESG Committee, the ESG Taskforce and the business departments to manage ESG-related matters of the Group from top to bottom, comprehensively control the ESG risks faced by the Group, and disclose the ESG situation to the stakeholders in the Report. In the future, the Group will continue to promote a top-down organisational culture of sustainability and facilitate the positive cycle of integrating sustainability into business processes.

Strategic Directions

The Group continues to deeply explore the Chinese market and clearly implement and align with the *Outline of the Plan for Healthy China 2030* blueprint in the following four directions:

Switching focus from "disease treatment" to "people's health"	Providing customers with the first line of assurance for their health	Improving the competitiveness of the medical device industry	Improving community-level service capabilities
To promote social health and disease prevention through charity activities in response to sudden health problems (stroke risk) caused by ageing population and extreme temperature differences;	To ensure that employees who provide customer service or are responsible for the sales process make "customer health and product safety" their top consideration and guarantee;	To cooperate with university research laboratories and young people to cultivate talents in the area of medical device development and industry innovation; and	To step up cooperation with community-level medicine and medical centres, and continue to expand our reach in primary markets.

Stakeholder Engagement

The Group values the opinions of our stakeholders and continuously listens to their feedback, treating them as an important reference for optimising our sustainability strategy and reprioritising work focus. We are committed to establishing effective communication mechanisms to maintain close engagement with stakeholders and to using a variety of channels to understand their expectations and requirements. By safeguarding stakeholders' rights to be informed and to participate, and by creating greater value for them, we will work together to advance sustainable development.

Categories	Issues of concern	Communication and response methods
Shareholders and investors	• Board diversity • Compliance operations • Anti-corruption • Anti-monopoly and unfair competition • Information security and privacy protection	Issuance of periodic reports and announcements General meeting Investor email
Employees	• Employee remuneration and benefits • Employee training and development • Occupational health and safety • Protection of employee rights and interests • Diversity and equal opportunities	Internal office system Regular communication Performance evaluation Training Team building activities Labour union

Categories	Issues of concern	Communication and response methods
Customers	• Product quality • Customer service • Complaints management • Information security and privacy protection • Compliance operations • Supplier management • Distributor and agent management	Customer service channels Customer satisfaction survey Management policy Contracts and agreements Examination and evaluation Daily communication
Business partners	• Supplier management • Distributor and agent management • Product quality • Customer service • Anti-monopoly and unfair competition • Compliance operations	Contracts and agreements Field inspection Research via questionnaire Examination and evaluation Daily communication
Government and regulatory departments	• Compliance operations • Anti-corruption • Anti-monopoly and unfair competition • Product quality • Medical waste discharge management • Energy and resource use and management	Information disclosure and submission Visit reception Award selection Supervision and inspection
Media	• Product quality • Customer service • Complaints management • Information security and privacy protection • Supplier management • Distributor and agent management • Social welfare • Responding to climate change	Daily communication and response Company official website news disclosure Interviews Award selection
Industry associations, hospitals and universities	• R&D and technological innovation • Product quality • Supplier management • Compliance operations • Anti-corruption • Industry cooperation and ecosystem building	Academic seminars Live surgical communication Industry exhibition Industry-education-research activities

MATERIALITY ASSESSMENT

The Group encourages shareholders, investors, the management, employees and partners to participate fully in stakeholder surveys and engages professional advisors to conduct materiality assessments through the following steps, so as to identify the Group's material issues and disclose the results of materiality assessments in an open and transparent manner.

1. Identification of material issues

Based on the nature of the business, the requirements of the Listing Rules, international reporting standards and the latest sustainable developments in the industry, and taking into account the Group's operating conditions, a list containing 24 material issues was established.

2. Assessment of material issues

A total of over 100 stakeholders from various groups, within and outside the Group, at home and abroad, were invited to participate in an opinion survey via questionnaire to score various material issues in terms of their materiality for stakeholders and the Group.

3. Analysis and confirmation of material issues

Based on the results of the stakeholder opinion surveys and management interviews, the scores of the various material issues were analyzed and validated, and, once confirmed, were used as an important reference for the Group's ESG strategy and the disclosures in the Report.

The materiality assessment results of the Group's 2025 ESG Report are illustrated as follows:



MATERIALITY ASSESSMENT

The top 10 key ESG Report issues for the Group and their relevant sections are as follows:

Issues		Relevant sections
1.	Product quality and safety	Product Quality and Safety
2.	R&D and technological innovation	R&D and Innovation
3.	Intellectual property protection	Protection of Intellectual Property Rights
4.	Employee health and safety	Health and Safety
5.	Information security and privacy protection	Information Security
6.	Quality customer services	Customer Service
7.	Responsible investment	Responding to Climate Change
8.	Employee benefits and talent attraction	Employee Benefits and Welfare
9.	Employee compliance, equality, diversity and inclusion	Employee Benefits and Welfare
10.	Employee development and training	Talent Management and Development

KEY SUSTAINABLE DEVELOPMENT AWARDS

Awarding institution	Name of award or charter
China National Intellectual Property Administration	"Medical Instrument Coating and Preparation Method Therefor and Medical Instrument Comprising Coating" won the 25th China Patent Excellence Award
The People's Government of Guangdong Province	"Promotion and Application of Key Technologies and Products for Interventional Treatment of Congenital Heart Disease in Children" won the 2024 Guangdong Science and Technology Achievement Promotion Award
The People's Government of Beijing Municipality	"Establishment and Domestic and International Promotion of a Minimally Invasive Treatment Technology System for Aortic Arch Diseases" won the Second Prize of the Beijing Science and Technology Award
Industry and Information Technology Bureau of Shenzhen Municipality	Honorary title of "Shenzhen Municipal Niche Champion Enterprise in Manufacturing"


广东省科技成果推广奖
证 书

为表彰 2024 年度广东省科技成果推广奖获得者，特颁发此证书。

项目名称：儿童先天性心脏病介入治疗系列关键技术及产品的推广应用

获 奖 者：先健科技（深圳）有限公司

粤府证【2025】2799 号
项目编号:T02-01-D06


北京市科学技术奖
科学技术进步奖
证 书

为表彰北京市科学技术奖获得者，特颁发此证书。

项目名称：主动脉弓部疾病微创治疗技术体系的建立及国内外推广
奖励等级：二等奖
获 奖 者：先健科技（深圳）有限公司

No.2024-J06-2-10-D03

UPHOLDING BUSINESS ETHICS AND OPERATING WITH INTEGRITY

Corporate Governance and Risk Management

The Group strictly complies with the *Company Law of the People's Republic of China* and other applicable domestic and overseas laws and regulations, regulatory rules and industry standards, and strictly implements the requirements of the *Corporate Governance Code* set out in Appendix C1 to the *Rules Governing the Listing of Securities on the Stock Exchange*. We uphold business ethics, maintain compliance and integrity, and pursue prudent operations while advancing our business layout and sustainable expansion in an orderly manner. Meanwhile, we continuously benchmark against leading international governance practices and improve our internal governance structures and operating mechanisms to ensure governance is conducted in a standardised, transparent and efficient manner.

As the Group's highest governance and decision-making body, the Board fulfils leadership, control and strategic oversight responsibilities, upholding a responsible, high-performance and sustainable governance philosophy to establish and maintain a high-standard corporate governance framework.

The Group has established an effective risk management system. The Legal Department is responsible for comprehensively identifying and monitoring Group-level compliance risks and managing them through pre-process prevention, in-process control and post-process handling, thereby ensuring the thorough implementation of risk management.

Pre-process prevention	• To establish, review and continuously improve corporate governance-related systems and business processes in accordance with the Group's development strategies and plans; • To provide corresponding legal support for key projects in the Group's operations, such as investment, financing, mergers and acquisitions, technology incubation, industry-academia-research cooperation, and provide compliance advice to decision-makers.
In-process control	• To continuously build and optimise the legal compliance structure of the Group and its domestic and overseas subsidiaries; • To continuously supervise and manage contracts, formulate and optimise contract templates, monitor contract performance, and prevent performance risks; • To draft, review, revise and archive the Group's system documents to ensure that the system complies with the latest regulatory requirements; • To continuously monitor the results of anti-corruption compliance and conduct due diligence on domestic and international distributors and agents; • To conduct compliance training to convey the Group's compliance policies and enhance employees' legal awareness.
Post-process handling	• To respond to and handle disputes, litigation and arbitration arising from the Group's operations in a timely manner and safeguard the Group's legitimate rights and interests.

To ensure all employees fully discharge their obligations regarding compliant business operations, the Group has established an ongoing compliance training framework focused on core industry compliance requirements. We provide targeted training on product compliance, quality system control, intellectual property protection, and anti-corruption/anti-bribery measures, among other specialised topics. We integrate high-quality internal and external training resources to align closely with domestic and international industry regulatory trends, the requirements of the Stock Exchange, and the Group's practical needs of the operation, thereby enhancing legal capabilities and improving work efficiency, and embedding compliance requirements deeply into our day-to-day workflows. Through systematic training and continuous promotion, we cultivate a culture of integrity and diligent performance among employees, ensuring all staffs rigorously observe compliance requirements and build a robust line of defence for the Group's compliance operations.

During the Reporting Period, the Group did not identify any illegal or irregular cases related to compliance and there were no compliance-related lawsuits against the Group or its employees.

Anti-corruption, Anti-bribery and Anti-competition

The Group upholds integrity and probity as core principles and strictly complies with applicable domestic and international laws and regulations and regulatory standards, including the *Law of the People's Republic of China on Supervision*, the *Law of the People's Republic of China on Anti-Money Laundering*, the *Anti-Unfair Competition Law of the People's Republic of China* and the *Interim Provisions on Prohibition of Commercial Bribery*. We conduct all aspects of our business in accordance with fair and impartial commercial practices, resolutely prohibiting any conduct that would impede, restrict or distort market competition. No improper commercial benefits shall be given to or solicited from any organisation or individual. The Group wholly prohibits commercial bribery, extortion, money-laundering and other forms of corrupt conduct in its daily operations, and is committed to safeguarding a clean and compliant operating environment.

To strengthen long-term defences against corruption, commercial bribery and unfair competition, the Group has established a suite of compliance management policies and has set out clear prohibitions and accountability measures in the *Employee Manual* regarding bribery, extortion, money-laundering and other corrupt behaviours. The Legal Department, Human Resources Department and relevant administrative functions work collaboratively to implement anti-corruption, anti-bribery and anti-unfair competition measures across the Group and to maintain ongoing control and oversight.

The Group has developed *LifeTech's Anti-Corruption Policy* to regulate the conduct of the Group and its partners in the course of cooperation. We explicitly prohibit all employees from offering or promising to offer any items of value or improper benefits to customers, government officials, suppliers, or partners, thereby preventing all forms of corruption and unfair competition at the institutional level. Any breach of this policy, its interpretative guidance or implementation procedures will be dealt with impartially; internal disciplinary measures will be imposed in accordance with Group rules, and employment will be terminated in cases of serious misconduct. At the same time, the responsible individuals may also be held civilly and even criminally liable by judicial authorities for breaching applicable anti-corruption laws and regulations in China and overseas. In selecting partners, the Group requires all candidates to carefully read and fully understand this policy and to sign an informed consent form, thereby ensuring effective implementation of the Group's anti-corruption requirements. *LifeTech's Anti-Corruption Policy* sets out the following red lines of conduct:

UPHOLDING BUSINESS ETHICS AND OPERATING WITH INTEGRITY

Damage to interests	Abuse of power, impure intentions, deliberate damage to the interests of the Company and the community.
Breach of integrity	Use of public power for personal gain, taking advantage of one's position to solicit or accept improper benefits.
Information leaks	Theft, disclosure or sale of confidential information such as the Company's intellectual property and technology, or inquiry into others' salary information.
Disregard for safety	Disregarding production and quality requirements, maliciously creating safety hazards.
Spreading rumours	Spreading statements that affect the Company's goodwill and spreading false and negative information.
Fraud	Lying at work, cheating the Group or its employees, concealing or harbouring malpractice.

Before commencing any cooperation or entering into a formal contract with a customer, the Group conducts comprehensive due diligence and verifies credentials, assessing the prospective counterparty's compliance practices, commercial integrity and risk management and contractual performance capabilities. At the same time, through a transparent and standardised contractual clause negotiation mechanism, we ensure that anti-corruption and anti-commercial bribery provisions are clearly defined and acknowledged in the contract, expressly requiring both parties to refrain from any form of commercial bribery, improper kickbacks or opportunistic profiteering. By building a robust compliance and risk control barrier from the outset of cooperation, we are committed to maintaining a fair and trustworthy business cooperation environment.

The Group conducts anti-corruption training for new employees every quarter. New employees are required to participate in the Group's anti-corruption training and learn relevant policies when they join the Group. Mentors of the employees are their respective superiors. They supervise and monitor each other at work, aiming to raise the anti-corruption awareness of all employees of the Group. During the Reporting Period, the Group has conducted 6 anti-corruption training sessions for directors, senior management and all new employees, with a total duration of 320.6 hours.

During the Reporting Period, the Group did not identify any illegal or irregular cases related to corruption and there were no corruption-related lawsuits against the Group or its employees.

Whistle-blowing Procedures

The Group has always upheld the core principle of integrity and compliance. We actively promote and encourage all employees and business partners to participate in an oversight system dedicated to ethical and honest conduct. The Group closely monitors employees' fulfilment of their duties with integrity, self-discipline and diligence, and promptly and effectively addresses any behaviour that may violate our code of conduct, internal policies, or applicable laws and regulations.

The Group has established an open and transparent compliance reporting and consultation system, offering multiple reporting channels for all employees, suppliers, distributors, and customers, including calling 0086-0755-86026250-8008 or sending an email to compliance@lifetechmed.com. Reports may be made anonymously to the heads of relevant departments or business contacts. The Group has clearly defined the whistle-blowing procedures and requires whistleblowers to submit information in good faith. Upon receiving a report, the Group's responsible department will respond promptly, mobilising both internal and external resources to conduct a rigorous and objective investigation into the matter. If any violation is verified, we will take appropriate corrective measures as necessary.

The Group has established a clear whistleblower protection mechanism and is committed to safeguarding whistleblowers' lawful rights and interests. During the investigation, all information provided will be kept strictly confidential, and any form of retaliation against the whistleblower is strictly prohibited. Should any retaliatory actions occur, we will address them severely in accordance with PRC and Hong Kong laws and regulations, and the Group's relevant policies, and anyone suspected of committing an offence will be held legally liable.

Information Security

The Group attaches great importance to information security and privacy protection, and strictly complies with relevant domestic and international laws and regulations, including the *Cybersecurity Law of the People's Republic of China*, the *Data Security Law of the People's Republic of China*, the *Personal Information Protection Law of the People's Republic of China*, the *Regulations on Network Data Security Management*, the *Administrative Measures for the Graded Protection of Information Security*, the *Personal Data (Privacy) Ordinance*, the *Regulations on the Protection of Technical Secrets of Enterprises in Shenzhen Special Economic Zone*, and the EU *General Data Protection Regulation (GDPR)*. We have established and refined a series of information security and privacy protection policies to safeguard the information assets of the Group and its partners. The Group continually strengthens full-chain network management, develops O&M standards and workflows, enhances security controls for server rooms, office environments and O&M sites, and refines mechanisms for account management, information review, routine inspections and emergency response. For urgent incidents, we maintain and refine contingency plans and conduct regular drills to ensure effective handling of network outages, cyber-attacks and information leaks, thereby enhancing our capability to respond to cybersecurity events.

Maintenance of Customer Data

The Group has developed *Confidentiality Agreements* for the collection of personal and customer data during business operations. These agreements regulate the use, collection and disclosure of data, guiding employees in the prudent handling of sensitive personal data and privacy information. We require that all employees sign *Confidentiality Agreements* and *Non-compete Agreements* upon joining the Group, which outline confidentiality obligations applicable to all positions and ranks within the Group. For specific roles, such as R&D personnel, technical specialists, and product data managers, the Group enhances confidentiality and non-compete clauses as required by the position. These clauses detail the trade secrets involved in the work content and documents pertinent to these roles and specify the confidentiality requirements for such information. During the Reporting Period, the Group did not identify any instances of employees violating the *Confidentiality Agreements* or *Non-compete Agreements*.

In addition, our contracts with customers stipulate that the Group undertakes to protect customer data, including but not limited to:

Technical information	Designs, drawings, specifications and moulds, etc.;
Commercial information	Sales information, customer list, product prices, purchase channels and product features; and
Other information	New product concepts or future development plans, etc.

Protection of Trade Secrets

Confidential information handled by the Group includes, but is not limited to, patented technologies, designs, process flows, technical reports, contracts and personnel records. We collect such information lawfully and provide clear explanations regarding the purpose and use of the collected information, ensuring that the owners of the information understand how it is utilised and protected by the Group. The Group has established a responsible department for maintaining systems, updating related equipment, and equipping all office computers with the latest antivirus software to protect and encrypt information and data.

The Group strictly prohibits any employee from disclosing, announcing, issuing, publishing, transferring and assigning, or otherwise providing any confidential information to any third party without proper authorisation or inadvertently. All suspected and confirmed cases of non-compliance with the relevant laws and regulations must be submitted to law enforcement authorities unless the management of the Group determines otherwise. The Group will not tolerate any illegal and improper behaviour of any individual. The Group will dismiss the employee concerned immediately after he/she has been adjudicated to have engaged in any misconduct or violation related to the Group's internal policies and requirements. Meanwhile, if any customer information has been disclosed, collected or used without authorisation resulting in any loss to the Group, the Group reserves the right, as applicable, to pursue legal action against the responsible party or entity.

During the Reporting Period, there were no confirmed violations or complaints about data privacy matters.

UNLEASHING INNOVATION VITALITY, ADVANCING TOGETHER WITH THE INDUSTRY

R&D and Innovation

The Group remains committed to its internationalisation strategy, actively expanding into overseas markets and exploring diversified business opportunities, with the aim of maintaining a global leadership position in product quality and technological innovation. We continually enhance our quality management system and strictly adhere to product quality standards to reinforce customer trust. Upholding technology-driven development, we steadily increase R&D investment and place strong emphasis on cultivating innovative talent, leveraging core technologies to secure market recognition. We are committed to creating a platform for co-creation and shared growth, reinforcing employees' sense of belonging and identity. The Group will continue to enhance product competitiveness and brand influence, bringing health and well-being to more patients through high-quality medical products. At the same time, we will maintain sharp market insight, proactively identify and evaluate strategic partnership opportunities, and continually bolster our competitive advantages and market position in both core and prospective target markets to realise our long-term strategic objectives in the global healthcare industry.

By sustaining R&D capabilities and strengthening our pool of scientific and technical talent, the Group continuously enhances product diversity and keeps the brand at the forefront of the market, thereby supporting steady business development and expansion. We strictly regulate product development processes and assign responsibilities within development teams to ensure R&D activities are conducted smoothly, with high quality and efficiency. Before initiating a project, the Group thoroughly understands the target market's needs, potential, and competitive landscape to set product design goals that meet market demands. In compliance with the regulations of its place of business, the Group demonstrates the clinical efficacy of products through clinical trials and completes local product registrations. In addition, multiple products under development will serve as strong supplements for sustained future growth.

Product Development Process



Product Development Teams:

Project Team	A cross-functional organisation primarily dedicated to product development, typically comprising the Product Development Department, Process Department, Regulatory Affairs Department, Manufacturing Engineering Department, Clinical Department, Medical Affairs Department, Testing Department, Design and Development Quality Control Group, and Project Management Representatives.
Support Team	A team formed by individuals or departments outside the project team that contribute to the project, typically comprising the Production Department, Quality Management Department, Supply Chain Department, Purchasing Department, Marketing Department, Engineering Department, and other project-related departments/personnel.

UNLEASHING INNOVATION VITALITY, ADVANCING TOGETHER WITH THE INDUSTRY

Our Products and Achievements

Innovative medical device products that are independently developed and manufactured in China maintain the competitive strengths of the Company, and also provide more effective treatments to patients around the world. In 2025, the Company continuously strengthened its innovation capabilities and accelerated the development of products, to maintain its leading position in the industry.

As of the year ended 31 December 2025, the Group made the following main progress in the R&D field:

- Thoracoabdominal Artery Stent Graft System (consists of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System, G-Branch™ AE Main Body Extension Stent Graft System, G-Branch™ AAA Bifurcated Stent Graft System and G-Branch™ IE Iliac Extension Stent Graft System), Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Aortic Arch Stent Graft System (consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System), Peripheral Balloon Dilatation Catheter (Large diameter), Yoscop™ Multi-loop Snare System, SteerEase™-m Introducer and LAA Closure Delivery System have obtained the NMPA certification;

- Ankura™ IIc TAA Stent Graft System has obtained the CE MDR (Medical Device Regulation) certification;

- Iliac Bifurcation Device (consists of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System), Peripheral High Pressure Balloon Dilatation Catheter and Yuranos™ Pro Abdominal Aortic Stent Graft System, etc. are pending registration approval in China;

- Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System, G-iliac™ Iliac Bifurcation Device, Thoracoabdominal Artery Stent Graft System (consists of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System, G-Branch™ AE Main Body Extension Stent Graft System, G-Branch™ AAA Bifurcated Stent Graft System and G-Branch™ IE Iliac Extension Stent Graft System) and Aortic Arch Stent Graft System (consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System) are pending registration approval of CE certification;

- CS™ Concave Supra-arch Branched Stent-Graft System, X-Clip™ Mitral Valve Clip System, Surecham™ Aortic Arch Single Branch Stent Graft System (consists of the Aortic Arch Stent Graft System and Aortic Branch Stent Graft System) and Congenital Heart Defect Occluder are currently at the stage of pre-registration clinical enrollment in China;

- Cera™ PFO Occluder has completed pre-marketing clinical enrollment and is currently under clinical follow-up in China;

- IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe, and its CE registration application has been submitted;

- IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the three-year follow-up of the phase II clinical study and two-year follow-up of the phase III clinical study. Currently, its CE and NMPA registration application have been submitted; and

- Congenital Heart Defect Occluder had been admitted into NMPA Special Examination and Approval Procedure for Innovative Medical Devices. It is the 16th product of the Company having obtained admission to the Procedure.

Industry Collaboration and Communication

In 2025, LifeTech continued to support academic conferences in key fields such as aortic and cardiovascular diseases in domestic and international markets, facilitating exchanges between domestic and foreign experts, as well as the interpretation of complex cases. This has also enhanced doctors' understanding of the Group's products, emphasised the importance of standardised surgical procedures, maintained our market presence, and promoted the development of the medical business. At the same time, we collaborated with medical institutions, industry associations, specialists and doctors to deliver the latest medical technologies and devices to less developed areas, striving to improve the global medical service.

We actively organised, funded, and participated in academic activities, taking on the social responsibility of disseminating academic knowledge and promoting disease prevention and treatment. We were also proactively involved in the formulation of international and national industry standards for related products, contributing our professional expertise to standardise product design and manufacturing. In addition, we actively sponsored international and domestic academic conferences, providing platforms for interactions with doctors and the industry while promoting the Company's products and culture.

UNLEASHING INNOVATION VITALITY, ADVANCING TOGETHER WITH THE INDUSTRY

International Marketing System	• A total of 87 academic conferences were held, including 46 national conferences, 11 international conferences and 30 regional conferences, with academic exchanges conducted with doctors from multiple countries and regions. In addition, 97 training sessions for doctors and agents were organised, effectively promoting information exchange, resource sharing, and collaborative development in the global medical field.
Structural Heart Marketing System	• A total of 129 academic conferences were held or participated in, including 26 national conferences (11 of which were linked with international events), 103 regional conferences. In addition, 12 training sessions for doctors and agents were organised, benefiting hundreds of doctors through these academic activities. We are dedicated to providing a smooth academic exchange platform for doctors specialising in left atrial appendage occlusion in China and worldwide, enhancing their understanding of surgeries and products, raising awareness of the importance of standardised surgical workflows, while maintaining strong brand visibility and fostering shared growth across the industry.
Peripheral Marketing System	• Over 100 online and offline academic events were planned and executed. Market promotion was advanced through diverse channels, including over 50 specialised E Physician events, satellite conferences, thematic seminars and academic salons; 20 national roadshows for the innovative aortic arch branch reconstruction product portfolio; more than 30 live and recorded surgical broadcasts; and over 20 department product presentations and workshops. These activities have offered industry experts opportunities for in-depth discussion and exchange on the latest research findings, provided a showcase platform for LifeTech's peripheral product portfolio, strengthened connections with medical experts, scholars and healthcare professionals at home and abroad, and offered robust support for the industry's long-term development.

National and International Academic Symposiums

Case 1 *The National Tour of Aortic Cavity Treatment Cases "China's Wisdom and Foresight"*

LifeTech continues to organise the National Tour of Aortic Cavity Treatment Cases "China's Wisdom and Foresight", a platform centred on real-world expert cases that provides customers with case demonstrations in both online and offline formats. Offline, we creatively combine "doctor" and "art" by means of third-party academic conferences and self-organised academic activities in the form of art exhibitions, holding a number of case exhibitions throughout the country. Online, we utilise our WeChat official account and other professional media platforms (such as CEC app, Clinic Endovascular, Vascular News, etc.) to showcase online case collections and provide detailed case analyses. Through this complementary online-offline approach, we present cases in greater detail, clarity and specificity, helping more target customers gain a deeper understanding of our products while offering valuable, actionable professional data and insights to medical practitioners. During the Reporting Period, the Group conducted 41 sessions of the National Tour, bringing the cumulative total to 95 sessions, featuring over 8,500 case presentations and involving more than 800 experts.

Case 2

Foresight · Leading & Healing E Physician - Case Analysis Academic Activities

LifeTech launched the Foresight · Leading & Healing E Physician - Case Analysis Academic Activities nationwide. Centred around the four dimensions of medical skills, technology, academics and art, these activities tell the story behind each case from a first-person perspective, interpreting the precise surgical strategies and standard surgical operations that underpin every successful case, and offering a comprehensive experience of the multifaceted expression of the art of life. During the Reporting Period, we conducted more than 50 sessions of the Academic Activities, bringing the cumulative total to 90 sessions, involving more than 3,000 experts.

Case 3

"United Arches, Healing Future" National Roadshow of Innovative Aortic Arch Product Portfolio

In 2025, LifeTech launched the "United Arches, Healing Future" National Roadshow of Innovative Aortic Arch Product Portfolio nationwide, bringing together diverse expertise to explore the forefront of technology. The roadshow provided comprehensive demonstrations and clinical exchanges around LifeTech's chimney technology system, featuring the Ankura™ Pro stent graft and the Longuette™ gutter-free branch stent graft; as well as the fenestration technology system, featuring the Ankura™ Plus stent graft, the self-adjusting gutter-free CSkirt™ branch stent graft, and the Futhrough™ in-situ fenestration device. These efforts have further advanced the standardised application of advanced technologies and promoted continued innovation in the aortic arch field.

Case 4

The 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC 2025) – VSD (Ventricular Septal Defect) Interventional Therapy Satellite Symposium

The 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC 2025) was held in Hamburg, Germany. During the event, LifeTech successfully hosted the VSD (Ventricular Septal Defect) Interventional Therapy Satellite Symposium. The Symposium was chaired by Professor Feldmann, Executive Chairman of the AEPC from the University Medical Center Hamburg-Eppendorf, and featured several internationally renowned experts who shared their clinical experience and research findings. These international distinguished structural heart experts noted that LifeTech's meticulously designed and high-quality KONAR-MF™ VSD Occluder is available in a wide range of models and is softer, making it suitable for smaller infants and young children. It can also be implanted via both antegrade and retrograde approaches, which not only greatly simplifies the surgical procedure but also provides patients with an additional treatment option, thereby reducing surgical risks. The experts marvelled at the rapid advancement of China's medical technology, which has enabled them to perform complex procedures that were previously impossible, allowing more patients to benefit.

Case 5

Annual Congress of the Latin American Society of Interventional Cardiology and the Mexican Society of Interventional Cardiology (SOLACI-SOCIME)

In 2025, the major flagship joint annual congress of the Latin American Society of Interventional Cardiology was held in Mexico. LifeTech made a prominent appearance with its innovative solutions in structural heart disease and peripheral intervention, engaging in discussions with top global experts on the future of interventional cardiology. During the congress, LifeTech showcased its cutting-edge advancements in occluder interventional technology. Through the Ceraflex™ dedicated satellite symposium, cutting-edge technology sharing sessions, and live case broadcasts, we actively participated in this academic event and received positive feedback from numerous international experts.

National and International Surgical Application Cases

Case 1

Brazil Congresso Internacional de Cirurgia Endovascular

In 2025, at the Congresso Internacional de Cirurgia Endovascular (CICE) held in Brazil, LifeTech carried out a cutting-edge live surgery broadcast spanning two hemispheres—inviting Professor Shu Chang from Fuwai Hospital, Chinese Academy of Medical Sciences, to perform a real-time remote demonstration of the Ankura™ abdominal aortic stent in vitro fenestration technique. During the procedure, the Ankura™ stent's outstanding flexibility and precise positioning ability enabled exceptional adaptability and stability in complex aneurysmal anatomy, while its well-established in vitro fenestration solution offered valuable reference for surgeons worldwide. This real-time China–Brazil online connection not only reflected the international recognition of Chinese experts' techniques and LifeTech's products, but also showcased an innovative model of global medical collaboration.

Case 2 *Sino-German Left Atrial Appendage Closure Salon*

In 2025, renowned German cardiovascular experts Prof. Karim Ibrahim and Dr. Frank Hennersdorf were invited to China to launch academic exchange activities focused on left atrial appendage closure in multiple locations. They visited Fujian Medical University Union Hospital, the Second Affiliated Hospital of Wenzhou Medical University, and Fuwai Hospital of the Chinese Academy of Medical Sciences, where they toured the facilities, participated in discussions, and observed procedures. These activities demonstrated the strength of these three leading hospitals in Fujian, Zhejiang, and Beijing in left atrial appendage closure, and also highlighted the unique advantages of LifeTech's LAmbre™ device in this field. China's top experts, together with the Chinese national product LAmbre™, showcased to visiting German specialists the superb skills of Chinese cardiologists and the strong capabilities of Chinese national brands, earning tremendous respect and recognition for China's innovative power.

Case 3 *Brazil Structural Summit*

In 2025, at the Brazil Structural Summit (BSS) on cardiac interventions held in São Paulo, Brazil, LifeTech's innovative LAmbre™ left atrial appendage occluder made a brilliant debut, and a highly challenging live procedure became the focus of the entire event. During the procedure, the LAmbre™ device's "integrated anchoring" design demonstrated outstanding manoeuvrability and stability, while its fully retrievable and redeployable features ensured procedural safety, earning high praise from the international experts on site. This live case was not only a demonstration of technique, but also compelling evidence that China's intelligent manufacturing has earned recognition from the world's leading surgeons.

Case 4 *CSI ASIA-PACIFIC*

In 2025, the CSI ASIA-PACIFIC conference was held in Bangkok, Thailand. During the live surgery session of the conference, Dr. Mann Chandavimol from the Faculty of Medicine Ramathibodi Hospital, Mahidol University in Thailand presented a highly challenging LAmbre™ procedure, fully showcasing the unique advantages of the LAmbre™ occluder: double-disc design, ease of use, and comprehensive range of sizes and specifications which make it suitable for a wide variety of complex left atrial appendage anatomies. It can be deployed without deep intubation of the appendage, providing a reliable and controllable solution for complex cases.

Case 5

CSI Focus LAA 2025

In 2025, the CSI FOCUS LAA 2025 was held as scheduled. The conference brought together leading experts from around the world to focus on the core topic of stroke prevention in atrial fibrillation, fostering in-depth academic exchange and forward-looking discussion across multiple dimensions, including anatomical imaging, transseptal puncture, synchronised atrial fibrillation ablation, live surgical demonstrations, complication management, the latest clinical interpretation, and innovative devices. During the conference, several internationally renowned experts used focused seminars and live surgery broadcasts to systematically showcase the product design concept and clinical performance of the LAmbre™ Left Atrial Appendage Closure System. These experts patiently guided participants through the standard LAmbre™ operating procedures and simulated real-world surgical operation processes, giving the participants a more intuitive understanding of the entire surgical procedure and the clinical features of LifeTech's LAmbre™ occluder. This initiative aims to empower more young physicians worldwide, helping them rapidly master standardised left atrial appendage occlusion techniques, and jointly driving the robust advancement of stroke prevention in atrial fibrillation.

Case 6

Supporting Ngari in Xizang in Completing Its First in Situ Fenestration Thoracic Endovascular Aortic Repair and Its First Interventional Operation for Congenital Heart Disease Using a Ceramic Occluder

In 2025, Director Jin Zhiyong led the Lifetech's peripheral vascular team at Ngari Prefecture People's Hospital in Xizang to successfully complete the region's first case of thoracic endovascular aortic repair (TEVAR) to seal the entry tear of an aortic dissection, while performing in situ fenestration to reconstruct the left subclavian artery and thereby preserve branch blood flow. In addition, under the leadership of Director Jin Zhiyong, the cardiology team at Ngari Prefecture People's Hospital in Xizang successfully carried out the region's first interventional procedure for congenital heart disease using a Cera™ ceramic occluder. During the procedures, multiple independently innovative supporting devices from LifeTech were used, including the AcuMark™ Sizing Balloon and the OKcurve™ Steerable Delivery System. From Shannan in Xizang to Ngari Prefecture, LifeTech has been deeply rooted in China's medical practice for many years, focusing on primary-level clinical needs. Leveraging breakthrough original innovations and a professional, efficient end-to-end technical support system, the Company is committed to extending high-quality healthcare resources to thousands of households, enabling more patients to access advanced medical services close to home and injecting strong impetus into the comprehensive advancement of the Healthy China Initiative.

Protection of Intellectual Property Rights

The Group owns multiple independent intellectual property rights and is fully aware that protecting intellectual property rights is crucial to our business development. The Group strictly complies with the *Patent Law of the People's Republic of China*, the *Trademark Law of the People's Republic of China*, the *Copyright Law of the People's Republic of China*, the *Anti-Unfair Competition Law of the People's Republic of China*, the *Measures for the Patent Work of Guangdong Enterprises* and other relevant regulations. Considering our specific circumstances, the Group has formulated the *Intellectual Property Work Management Measures* and established dedicated systems for the management of patents, trademarks and trade secrets. We have compiled the *Intellectual Property Management Manual* in accordance with GB/T 29490 *Enterprise Intellectual Property Management*, and we continuously improve our intellectual property management system to enhance the efficiency of enterprise intellectual property management. We have obtained the appraisal certificate for innovation and intellectual property management capability based on ISO 56005.

IMSPP

IMSPP-G002IIPMC24-CN-000401-01

基于 ISO 56005 的《创新与知识产权管理能力》
等级证书（2 级）

先健科技（深圳）有限公司

（地址：深圳市南山区粤海街道高新区社区科技南十二路22号先健科技大厦8层）

经评价，已通过并达到了《创新管理 - 知识产权管理指南（ISO 56005: 2020）》及相应的《创新与知识产权管理能力分级评价指标体系》相关能力要求，特发此证书。

评价范围：心血管疾病的微创介入医疗器械领域创新过程中的知识产权管理

发证日期：2024-12-13　　有效期至：2027-12-12

查询平台：https://grading.imspp.org.cn

评价机构：中规（北京）认证有限公司　　（签章）

The Group has formulated the *Management Measures for Technical Secrets* to protect technical secrets related to R&D and production. Our confidentiality control measures are as follows:

Internal measures	• Employees are required to sign *Non-compete Agreements* and *Confidentiality Agreements*; • For products and projects with higher confidentiality, relevant personnel are designated and project data access is granted exclusively to these individuals; • Patent applications are strategically planned, with delayed publication of such applications; • Specific requirements are established for product circulation.
External measures	• *Confidentiality Agreements* are required before seeking external consultations regarding highly confidential products; • Contracts for outsourced production, mould development, raw materials supply, etc., explicitly include intellectual property clauses to delineate rights and responsibilities.

UNLEASHING INNOVATION VITALITY, ADVANCING TOGETHER WITH THE INDUSTRY

The Group has set up an Intellectual Property Department to take full responsibility for relevant matters concerning intellectual property rights, protect the intellectual property rights of the Group and ensure that no infringement occurs in the Group. The Intellectual Property Department exercises overall management of the Group's proprietary intellectual property rights and keeps detailed statistics and records. It also has the following responsibilities in relation to policy and regulatory monitoring, infringement risk identification, intellectual property training, and other areas:

Policy and regulatory monitoring	• The Group adopts structured design and development control procedures to monitor the entire design and development process of all products. The Intellectual Property Department regularly communicates with the Research and Development Department to ensure that all product design and development comply with the legal and regulatory requirements of the target countries or regions of registration, thus ensuring the quality of design and development and ensuring product safety and effectiveness.
Infringement risk identification	• The Intellectual Property Department keeps abreast of the situation of peer companies and similar products. If the intellectual property rights of the Group are at risk of infringement, the Intellectual Property Department adopts various methods to protect different types of intellectual property rights, such as invention patent protection, utility model patent protection and appearance patent protection, to ensure that the intellectual property rights of the Group are fully protected. • The Intellectual Property Department conducts strict supervision and control over whether its products constitute infringement, so as to prevent infringement. In all aspects of the R&D cycle, including preparation, initiation and clinical animal experiments, the Intellectual Property Department communicates closely with the Research and Development Department to promptly synchronise product development status and compare the appearance, features, technology, and usage of similar products globally to ensure that the products under development are free from infringement, thereby ensuring the smooth advancement of the Group's R&D projects.
Intellectual property training	• The Intellectual Property Department provides intellectual property-related training to relevant departments such as the Research and Development Department and Production Department that are exposed to the Company's core technologies, so as to strengthen the intellectual property awareness of technical employees and protect the information security in all aspects of product production and research and development.

The Group holds a total of 2,943 intellectual property rights, including 1,217 approved and valid patents. During the Reporting Period, 271 new patents were added, 312 trademarks were registered in aggregate, and the Group undertook 7 government scientific research projects. During the Reporting Period, the Group incurred compliance expenditures of approximately RMB 1,550,000 for new product registrations, registration changes and certificate renewals for marketed products.

To continuously foster a culture of R&D and innovation and to strengthen the driving force of intellectual property innovation, the Group has formulated the *Patent Reward Policy*, established a comprehensive R&D innovation incentive system, and implemented R&D incentives through dedicated funding. For inventors and R&D teams involved in patent applications, patent grants, and patent implementation—particularly those who have obtained substantial gains from the independent exploitation and commercialisation of intellectual property—the Group pays remuneration in accordance with relevant national regulations. By establishing long-term, standardised incentive mechanisms, the Group fully motivates employees to engage in patent R&D and intellectual property portfolio planning, continuously energises its overall R&D innovation, and promotes the efficient realisation of intellectual property value.

The Group is committed to protecting its own intellectual property rights from infringement and also respects the intellectual property rights of its business partners and third parties. To strengthen intellectual property constraints and protection throughout the entire cooperation process, the Group specifies clauses on mutual respect for and protection of intellectual property in the *Confidentiality Agreements* it signs with different business partners, clearly defining the rights and obligations of all parties to the cooperation. To address potential intellectual property violations that may arise during cooperation, the agreement clearly specifies the primary liability for violations. Individuals and entities in breach are required to bear the corresponding consequences in accordance with the law, including but not limited to compensating for economic losses, accepting legal arbitration, and accepting other agreed penalties, thereby regulating cooperative conduct at its source and fostering a compliant, orderly, and trustworthy business cooperation environment.

During the Reporting Period, the Group was not involved in any confirmed violations or complaints concerning intellectual property matters.

CONSOLIDATING QUALITY ASSURANCE AND ENHANCING PRODUCT QUALITY

The Group closely monitors market developments at home and abroad and continues to expand its cross-border business. Our business spans the mainland, Hong Kong, Macao, and Taiwan of China, and extends to Europe, Latin America, Southeast Asia, the Middle East and Africa, and the Commonwealth of Independent States. Relying on the Group's overall strategic layout and the pace of its overseas expansion, the Group has always regarded compliance operations as the fundamental baseline for conducting business. It proactively tracks regulatory developments, conducts in-depth study of, and strictly implements all applicable laws and regulations in each jurisdiction where it operates, consistently striving to meet the highest local regulatory standards and making every effort to ensure that its global business operations remain compliant, stable, and sustainable.

Product Quality and Safety

Quality Management System

Product quality is the cornerstone of a company's survival and sustainability. The Group deeply understands the significant responsibility and importance of medical device quality in patient recovery and even life support. We strictly comply with the *Product Quality Law of the People's Republic of China*, the *Medical Device Administration Law of the People's Republic of China*, the *Measures for the Supervision and Administration of the Quality of Medical Device Use*, the *European Union Medical Device Regulation (MDR),* the specialised medical device regulations and implementation guidelines promulgated by the member states of the European Union, as well as the relevant regulatory requirements and technical guidelines issued by other overseas countries and regions.

The Group is committed to maintaining high product quality standards, having established and continuously improved the quality management system. By implementing a sound product quality control process, we ensure control over various steps of production. The Group has obtained certification under the ISO 13485 medical device quality management system, and its domestic and overseas subsidiaries are also actively obtaining and maintaining the corresponding certifications. The Group's laboratories have obtained certification under the ISO 17025 laboratory quality management system. The Group has also implemented the Medical Device Single Audit Program (MDSAP), meeting the standards and regulatory requirements of medical device markets in five countries, including Australia, Brazil, Canada, Japan and the United States. During the Reporting Period, the Group incurred certification expenses of approximately RMB 1,270,000 in European Union, MDSAP, South Korea, Russia and Ukraine to obtain medical device quality management system certification.

DEKRA

CERTIFICATE

Number: 2107230

The management system of the organization(s) and locations mentioned on the addendum belonging to:

Lifetech Scientific (Shenzhen) Co., Ltd.
8F, LifeTech Scientific Building,
No. 22
Keji 12th Road South
High-tech Industrial Park
Yuehai Subdistrict
Nanshan District
Shenzhen 518063
P.R. China

including the implementation meets the requirements of the standard:

EN ISO 13485:2016

Scope:
Design and development, production and distribution of endovascular and cardiovascular implants, delivery systems and accessories:
Vena Cava Filters, Occluder / Closure Implants and associated Delivery Systems, Steerable Introducers, Vascular Plug and Delivery Systems, Snare Systems, Sizing Balloons, Stiff Guidewires, Stent Graft Systems and Associated Delivery Systems, Introducer Sheaths, Dilators, Endovascular Needle Systems for Intra Cavity Reconstruction of Stent Grafts, Open Surgery Stent Graft Systems, Bioresorbable ASD Occluders and Delivery System, PTA Drug Eluting Balloons and Stent Graft Balloon Catheter.

Production of Lung Volume Reduction Reverser implantable devices and associated delivery systems.
The provision of Ethylene Oxide sterilization services fulfilling applicable quality management system requirements within EN ISO 11135:2014 and ISO 11135:2014.

Contract Manufacture of Endovascular and Cardiovascular Implantable Devices and associated Delivery Systems: Vena Cava Filters, Occluder / Closure Implants and associated Delivery Systems, Steerable Introducers, Vascular Plug and Delivery Systems, Sizing Balloons, Stent Graft Systems and Associated Delivery Systems, Introducer Sheaths, Dilators, Endovascular Needle Systems for Intra Cavity Reconstruction of Stent Grafts, Open Surgery Stent Graft Systems, and Trans-Carotid Artery Occlusion Shunt System.

DEKRA Certification B.V.

B.T.M. Holtus
Managing Director

J.M. McKenzie
Certification Manager

© Integral publication of this certificate and adjoining reports is allowed

IAF

DEKRA Certification B.V. Meander 1051, 6825 MJ Arnhem P.O. Box 5185, 6802 ED Arnhem, The Netherlands
T +31 88 96 83000 F +31 88 96 83100 www.dekra.nl Company registration 09085396

bsi.

By Royal Charter

Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016 & EN ISO 13485:2016
持有证书 ISO 13485:2016 & EN ISO 13485:2016

This is to certify that: 兹证明
Lifetech Scientific (Shenzhen) Co., Ltd.
8F, LifeTech Scientific Building
No 22, Keji 12th Road South, High-tech Industrial Park
Yuehai Subdistrict, Nanshan District
Shenzhen
Guangdong
518063, China

先健科技（深圳）有限公司
91440300715217115L
中国
广东省
深圳市
南山区粤海街道
高新区科技南十二路22号
先健科技大厦8层
邮编：518063

Holds Certificate No: 持有证书 **MD 611570**

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 & EN ISO 13485:2016 for the following scope:
并运行符合 ISO 13485:2016 & EN ISO 13485:2016 要求的质量管理体系，认证范围如下：

Design, development, manufacture and distribution of endovascular and cardiovascular implants, delivery systems and accessories. Contract manufacture of Distal access catheter kits, Balloon Guiding Catheters, Aspiration Catheters and Aspiration Pumps in the area of neurovascular and cardiovascular procedures.
血管内及心血管内植入器械、输送系统及配件的设计开发、制造及分销。 用于神经血管和心血管手术领域的远端通路导管套装、球囊导引导管、颅内血栓抽吸导管及血栓抽吸负压吸引泵的合同制造。

For and on behalf of BSI:
BSI代表：

Graeme Tunbridge, Senior Vice President Global Regulatory & Quality

Original Registration Date 首次发证日期: 2020-08-08
Latest Revision Date 最新发证日期: 2025-04-17
Effective Date 生效日期: 2023-08-04
Expiry Date 有效期至: 2026-08-03

Page: 1 of 2

...making excellence a habit.

bsi.

By Royal Charter

Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that:
Lifetech Scientific (Shenzhen) Co., Ltd.
8F, LifeTech Scientific Building
No 22, Keji 12th Road South, High-tech Industrial Park
Yuehai Subdistrict, Nanshan District
Shenzhen
Guangdong
518063
China

Facility ID Number: F005104

Holds Certificate No: **MDSAP 725656**

The company listed on this certificate has been audited to and found to conform with ISO 13485:2016 including the following country specific requirements:

Australia: Therapeutic Goods (Medical Devices) Regulations, 2002, Schedule 3 Part 1 (excluding Part 1.6) - Full Quality Assurance Procedure
Brazil: RDC ANVISA n. 67/2009, RDC ANVISA n. 665/2022 - Good Manufacturing Practices, RDC ANVISA n. 551/2021
Canada: Medical Devices Regulations - Part 1 - SOR 98/282
Japan: MHLW MO No 169 (2004), as amended by MHLW MO No 60 (2021), PMD Act
USA: 21 CFR 820, 21 CFR 803, 21 CFR 806, 21 CFR 807 - Subparts A to D, 21 CFR 821

Design, development, manufacture and distribution of endovascular and cardiovascular implants, delivery systems and accessories.

For and on behalf of BSI:

Graeme Tunbridge, Senior Vice President Global Regulatory & Quality

Original Registration Date: 2020-08-04 Effective Date: 2025-09-08 Expiry Date: 2026-08-03

Page: 1 of 2

MDSAP

...making excellence a habit.



ilac-MRA CNAS

中国合格评定国家认可委员会
实验室认可证书

（注册号：CNAS L18015）

兹证明：

先健科技（深圳）有限公司测试中心

（法人：先健科技（深圳）有限公司）

广东省深圳市南山区高新技术产业园南区科技南十二路 22 号先健科技大厦负 4 层、8 层、10 层（微粒室）和 11 层，518063

符合 ISO/IEC 17025：2017《检测和校准实验室能力的通用要求》（CNAS-CL01《检测和校准实验室能力认可准则》）的要求，具备承担本证书附件所列服务能力，予以认可。

获认可的能力范围见标有相同认可注册号的证书附件，证书附件是本证书组成部分。

生效日期：2025-05-26
截止日期：2029-03-22

中国合格评定国家认可委员会授权人 张朝华

中国合格评定国家认可委员会（CNAS）经国家认证认可监督管理委员会（CNCA）授权，负责实施合格评定国家认可制度。CNAS是国际实验室认可合作组织（ILAC）和亚太认可合作组织（APAC）的互认协议成员。
本证书的有效性可登陆www.cnas.org.cn获认可的机构名录查询。

CONSOLIDATING QUALITY ASSURANCE AND ENHANCING PRODUCT QUALITY

The Group has developed various product quality management regulations, such as the *Material Specification Template*, *Design and Development Control Procedure*, *Production Process Control Procedure*, *Inspection and Test Control Procedure*, *Sterilisation Confirmation Procedure*, and *Finished Product Release Procedure*, to ensure compliance with regulatory and the Group's requirements. The Group has set up a Quality Management Department, clearly delineating the responsibilities for product quality control at the development, production, and market launch stages.

During the product inspection phase, our products are regularly inspected for quality by qualified engineers with relevant experience and tested by laboratories accredited by the China National Accreditation Service for Conformity Assessment ("CNAS"). We continue to introduce automated and semi-automated product inspection methods and equipment to improve the efficiency and effectiveness of product quality testing.

Standardised Procedure

The Group has formulated a range of policies and procedures that specify quality control requirements for products and clinical trial samples, ensuring that products meet the technical requirements of different countries and industries.

- *Clinical trials*

The Group's Clinical Department conducts clinical trials in accordance with regulations and guidelines of respective countries and complies with the *World Medical Association Declaration of Helsinki* to ensure compliance with the ethical principles for human-based biomedical research. The Clinical Department has also established the following key operational procedures to actively track and report all kinds of events incurred in clinical trials so as to ensure the identification of risks arising from human-based research and standardised operation:



The Group has established a clinical inspection team mainly responsible for the comprehensive inspection of the marketed clinical projects and outsourced clinical programs operated by the Company to ensure the supervision of trial quality over the clinical trial process. In addition, third-party experts have also been invited to conduct external inspections for some programs and centres. We expect to ensure the safety and effectiveness of the marketed products through the complete inspection process so as to meet the requirements of the tightening regulations at home and abroad.

- *Sterilisation process*

The products of the Group are sterile or sterile implanted medical devices, with extremely stringent requirements for aseptic performance. To ensure the aseptic performance of the products, the Group rigorously monitors the sterilisation process in accordance with the requirements of the *Sterilisation Confirmation Procedure* and the detailed rules of the *Development, Validation and Routine Control Procedures for Ethylene Oxide Asepsis Processes*. In addition, the Group strictly implements the relevant provisions of the *Monitoring and Measurement Device Control Procedure*. For all equipment and instruments used to monitor the entire sterilisation process, it rigorously controls calibration accuracy, operational stability and reliability to ensure precise and effective monitoring of the sterilisation process, thereby providing strong support for products' aseptic performance.

- *Finished product inspection and release*

The Group rigorously carries out specialised testing procedures such as destructive testing and sterility testing at the finished product inspection stage, comprehensively verifying all performance indicators of its medical devices to ensure that product performance and safety indicators meet applicable standards and clinical requirements. All finished products strictly comply with the Group's relevant specifications under the *Finished Product Release Procedure*, and may only be released after all tests have been completed and all indicators have met the required standards.

- *Control of non-conforming products*

The Group strictly controls product quality and safety. Any non-conforming or substandard materials found in any stage of production will be strictly dealt with in accordance with the *Control Procedures for Non-Conforming Products* to ensure that they can be properly identified, recorded, assessed, separated and disposed of. If it is necessary to use a non-conforming product or part, the Group shall confirm that such use will not affect the safety, effectiveness or performance of the finished product.

CONSOLIDATING QUALITY ASSURANCE AND ENHANCING PRODUCT QUALITY

Contamination Prevention and Control Management

To ensure no contamination in our raw materials, production process and finished products, and show our responsibility for product quality and safety, the Group implements the following control measures for contamination prevention and control:

Set up contamination prevention and control areas 	Divide the transportation area into the incoming cargo area and the delivering area, and establish clear signs and isolation measures between the two areas. Ensure that transportation vehicles, pallets and personnel can only move within the designated area.
Sealed storage of raw materials and products 	All raw materials and products are wrapped and covered in sealed plastic bags to prevent contamination during transportation.
Strengthen worker health management 	All relevant employees are required to undergo health checks before joining the Group, and the Group provides annual physical health checks for employees. Employees are required to wear protective equipment such as gloves, masks and goggles at work.
Regularly inspect and evaluate contamination prevention and control measures 	Regularly evaluate and inspect contamination prevention and control measures to ensure that all measures are effectively implemented and adjusted and improved according to the actual situations.
Establish an emergency plan 	Develop an emergency plan for possible contamination situations, so that in the event of contamination, measures can be taken quickly to reduce the impact of contamination.
Train and educate employees 	Train and educate employees on contamination prevention and control to enhance their awareness and ability to operate as required.

Product Responsibility

The Group values the management of product responsibility and strictly abides by national laws and regulations such as the *Regulations on the Supervision and Administration of Medical Devices* and the *Provisions for Instructions and Labels of Medical Devices,* and regards standardised product label management as a key link in fulfilling product responsibility and safeguarding users' rights and interests.

To standardise the management of product labels, the Group has formulated the *Language and Label Control Procedures* and established a standardised and systematic product label management mechanism. The Group's Registration Department is responsible for reviewing the regulatory compliance of labels and updating the latest information of supervision institutions and laws and regulations to relevant departments in due course. Meanwhile, our Product Development Department is responsible for providing details of products, guaranteeing the customers' and users' right to know. Before each set of product labels is officially finalised and issued, the relevant responsible departments conduct repeated checks to ensure that the label information is truthful, accurate, standardised, clear, and compliant with regulatory requirements.

The Group complies with the product liability and product liability insurance requirements of different countries and has taken out product liability insurance for all of our products. If an accident or personal injury is caused by product-related issues, the Group will fully cooperate with the relevant judicial proceedings, assume the corresponding compensation liability in accordance with the law, and effectively safeguard the legitimate rights and interests of consumers and other relevant parties. At the same time, the Group adheres to the risk management principle of "prevention over remediation," and, from the initial stages of product design and development, actively carries out comprehensive identification and assessment of potential product risks so as to minimise safety accidents and personal injuries. For any identified potential product risks, the Group truthfully includes them in product labels, while also providing professional product-use training to customers and clinicians, establishing robust feedback channels, actively listening to feedback from clinical use and the market, and continuously optimising product design and performance to drive ongoing improvements in product quality.

During the Reporting Period, there were no accidents involving the use of the Group's products that resulted in injuries or fatalities.

The Group is regulated by the laws and regulations such as the *Advertising Law of the People's Republic of China*. As the Group has not published any product advertisements facing the public yet, no relevant policies have been formulated. The Group will formulate relevant policies to standardise the promotion content of advertisements of products and services in future (if necessary). If the publication of introductions and functions of products is needed, the Group will truly describe such products and carefully review materials, so as to ensure the accuracy of the contents.

During the Reporting Period, there were no relevant violations of laws or regulations relating to improper product label and advertising management of the Group.

CONSOLIDATING QUALITY ASSURANCE AND ENHANCING PRODUCT QUALITY

Customer Service

The Group consistently adheres to a customer-centric service philosophy, makes every effort to provide high-quality, professional customer services, strictly complies with relevant laws and regulations such as the *Law of the People's Republic of China on Protection of Consumer Rights and Interests* and the *Regulation on the Implementation of the Law of the People's Republic of China on Protection of Consumer Rights and Interests*, and effectively safeguards the legitimate rights and interests of consumers. The Group attaches great importance to customer opinions and market feedback, regularly conducts customer satisfaction surveys, and comprehensively collects customer needs and service suggestions. In response to customer complaints and related requests, the Group has established a rapid-response and closed-loop handling mechanism to ensure timely follow-up and efficient resolution of various issues, to fully facilitate the satisfactory resolution of customers' reasonable requests and continuously enhance the quality of customer services and the level of cooperation satisfaction.

Customer Satisfaction

The Group regards customer satisfaction surveys as an important mechanism for understanding customer needs, optimising customer experience, improving product and service quality, and strengthening brand competitiveness. The Group regularly conducts annual customer satisfaction surveys and systematically collects customer feedback through questionnaires. The Group then carries out in-depth analysis and refined categorisation of the feedback across multiple dimensions, including product types (e.g., stent, occluder), packaging conditions, and customers' geographical distribution. On this basis, the Group identifies feasible optimisation measures and improvement points in each area, and develops and implements tailored improvement plans. Through customer satisfaction surveys, the Group continuously tracks customer needs and expectations, is committed to building long-term and stable partnerships with customers, and drives the sustainable development.

Customer Complaints Management

The Group values customer feedback on our products and services, and regards the handling of customer complaints as an important reference for improving quality and enhancing services. The Group has formulated the *Processing Procedure for Customer Complaints*, which clearly standardises complaint intake channels, end-to-end handling rules, and the division of responsibilities among departments, thereby establishing a standardised, closed-loop complaint management system.

The Group strictly enforces a rapid response mechanism for complaints. Whenever a customer complaint is received, the responsible department must provide an initial response within 24 hours, proactively communicate with the customer, and thoroughly verify and record the cause of the complaint, the products involved, and the specific circumstances, ensuring that the facts of the complaint are clear and fully traceable. If, upon verification, the complaint is found to be valid, the Group will immediately appoint dedicated personnel to conduct an in-depth investigation, thoroughly analyse the root causes of the issue, and formulate and implement targeted corrective and preventive measures to prevent similar issues from recurring. The entire investigation process, handling results, and related materials will be centrally archived and managed to ensure full-process reviewability and traceability.

In addition, to reduce the risk of customer complaints at the source and prevent similar issues from recurring, the Group has established an ongoing complaint trend analysis mechanism. At least once a year, it conducts a comprehensive consolidation and trend analysis of customer complaint data, identifies and refines improvement directions for high-frequency issues and common potential risks, and promptly feeds the results back to relevant functions such as R&D, production, quality control, and service. In this way, the Group continuously improves its internal control and service processes, effectively safeguards customer rights and interests, and strengthens long-term, stable customer relationships.

During the Reporting Period, the Company received a total of 75 product quality complaints related to occluders, delivery sheaths, large stents, vena cava filters and implantable cardiac pacemakers, as well as 1 product label complaint related to occluders. All complaints were handled in a timely manner in accordance with the *Processing Procedure for Customer Complaints*.

Product Recall

If customers identify any quality issues or experience any related adverse events while using the Group's products, the Group will strictly follow the *Processing Procedure for Customer Complaints*, *Adverse Event Reporting Procedures*, and all applicable laws and regulations to conduct a comprehensive investigation, carry out root cause analysis, and take standardised corrective actions. Throughout the entire process, we fulfil our medical device product risk management responsibilities.

If subsequent remedial measures are required after product delivery, the Group will, in accordance with the relevant provisions of the *Notice of Advice and Recall*, promptly issue a notice of advice for the purpose of supplementing product information or providing scientifically sound and appropriate handling recommendations. Where necessary, we will lawfully initiate the product recall process to fully prevent and control risks associated with product use. For all product quality issues and any resulting recall actions, the Group will promptly and truthfully report to the relevant regulatory authorities in accordance with regulatory requirements, ensuring full compliance, transparency, and traceability throughout the process.

During the Reporting Period, the Group had no major incidents in which the Group was punished by regulatory departments, and none of the Group's products was recalled due to major quality problems or health and safety reasons.

CONSOLIDATING QUALITY ASSURANCE AND ENHANCING PRODUCT QUALITY

Supply Chain Management

Procurement Management

The Group fully recognises the critical importance of supply chain management for the stable operation of our overall business and for controlling product quality at the source. Supply chain risk prevention and control have been incorporated into the Group's management system, and internal management systems such as the *Purchasing Practice Guide* and *Purchase Control Procedures* have been formulated. A standardised, end-to-end procurement management system has been established to achieve unified control, risk prevention, and dynamic monitoring across the entire procurement chain, thereby laying a solid foundation for stable business operations from the source.

To ensure that supplier qualifications and service capabilities meet the Group's procurement standards and quality requirements, the Group's Purchasing Department, Quality Management Department and Research and Development Department work closely together to screen suppliers and conduct access reviews. They carry out comprehensive, multi-dimensional assessments of suppliers, covering compliance with commercial terms, procurement costs, product and service quality, R&D and innovation capability, production and manufacturing standards, and after-sales service support, and carefully select high-quality, compliant suppliers as partners. Composition of the supplier management teams and their major responsibilities are as follows:

Purchasing Department:	• responsible for purchasing materials and equipment needed in the production and R&D process of the Group based on the requirements of the requiring department; • responsible for overall supplier management through supplier development and evaluation, business negotiation, order management and supplier performance management; • responsible for adjusting the procurement guidelines and supplier codes by considering market demand and the actual situation of the Group.
Quality Management Department:	• responsible for verification and inspection of materials provided by suppliers as well as product testing.
Research and Development Department:	• responsible for providing the purchasing needs and requirements of materials and equipment needed in the production and R&D process; • responsible for quality risk evaluation on suppliers and participation in supplier selection.

The Group has established a comprehensive and standardised procurement control system and has developed and continuously refined a dual-core management framework for supplier access evaluation and supplier operation evaluation. Together with full-process control mechanisms and efficient management methods, this framework forms a closed loop for supplier management, covering key stages such as preliminary supplier screening and comprehensive evaluation, targeted audits of quality systems, scheduled annual supplier reviews, and surprise on-site audits.

To further standardise supplier evaluation, the Group has formulated the *Supplier Evaluation Guidelines*, which clearly define supplier selection criteria and standardised operating procedures. The main processes are as follows:



The Group formulates an annual supplier audit plan and conducts supplier reviews. We classify our suppliers into four classes (A, B, C and D) and implement corresponding audit and management measures for each class. We conduct annual on-site audits for Class A suppliers and annual document-based audits for Classes B, C and D suppliers. If the quality of Class A suppliers is abnormal, the Group will immediately conduct on-site audits. A comprehensive evaluation is carried out in four aspects: supplier quality data, delivery information, service capabilities and price levels. Inspection covers all seven aspects, including document control system, material control, production process control, quality control, packaging/transportation, measuring and testing equipment control and environment. Based on the assessment findings and potential risks, the Group formulates plans and conducts audits. If suppliers cannot meet the relevant requirements, they will be required to complete the rectification within the time limit. If the requirements are still not met, the cooperation with the supplier will be terminated.

The Group has detailed technical requirements for the required raw materials and corresponding incoming inspection operation requirements. After the raw materials provided by the supplier arrive at the Group, the checksum has to be performed and the raw materials have to be tested. After testing, qualified raw materials will be registered for storage and use, while unqualified materials will be returned to the supplier.

In addition, for core raw materials used in production and manufacturing, the Group has established an alternative supplier mechanism, while continuously expanding supply channels and developing potential high-quality new suppliers. Through a diversified supply network, the Group effectively mitigates the risk of raw material shortages, avoids disruptions to its normal production capacity and delivery schedule, and ensures the continuous and stable progress of its production and operations.

During the Reporting Period, the Group had a total of 207 major suppliers, of which 184 were from the Chinese mainland and 23 were from other regions such as the United States and Singapore. We ensure that all suppliers are evaluated comprehensively through management mechanisms such as access evaluation and operation evaluation.

Sustainable Procurement

Sustainable procurement is one of the important strategies for enterprises to achieve long-term development and practice social responsibility. Consistent with the trend of sustainable development, the Group has consciously added environmentally-friendly raw materials, energy-efficient technologies and equipment, protection of labour rights and interests, fulfilment of social responsibility, business ethics and other relevant factors when selecting suppliers to adjust procurement requirements accordingly. The Group is committed to promoting the sustainable development of the industrial chain and enhancing the resilience and risk response capability of the supply chain by improving resource utilisation efficiency, reducing waste and reducing energy consumption.

The Group puts forward further requirements for specific suppliers, such as requiring relevant suppliers to provide corresponding test reports on heavy metal content, ethylene oxide residue and sterility testing, and also requiring suppliers in the industry of polymer materials and nickel-titanium wire material to provide a declaration that their products conform to the *Regulation Concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals* ("REACH[1]") so as to ensure the Group's products meet the requirements of both domestic and foreign markets.

The Group continues to promote green procurement, actively implementing domestic substitution verification of key raw materials during the Reporting Period, and consciously controlling the procurement and transportation time, thus continuously optimising the production cycle and improving production efficiency. The Group consciously prioritises the use of certified green products and equipment with energy-efficient labels, and cooperates with suppliers with good corporate social responsibility performance or environmental management system certificates.

		2025	2024
Suppliers and distributors with environmental certifications/qualifications *(such as ISO 14001, ISO 50001, ISO 22000)*	Number	120	120
Materials purchased passing environmental tests *(such as RoHS[2], REACH)*	Percentage of total procurement (%)	90%	90%
Materials obtained an environmental protection certification/qualification *(such as FSC[3])*	Percentage of total procurement (%)	80%	80%
Preferential target to purchase from local suppliers	Percentage of total procurement (%)	92%	90%

1 REACH aims to protect the health of human beings and the safety of the environment, maintain and enhance the competitive advantages of the EU chemical industry, improve the innovation capability of enterprises and achieve the goal of sustainable social development.

2 RoHS refers to the Restriction of the Use of Certain Hazardous Substances in Electrical and Electronic Equipment. The EU Parliament and the EU Council adopted the RoHS directive in January 2003, also known as the 2002/95/EC directive.

3 FSC (Forest Stewardship Council), also known as wood certification, is a tool to use market mechanisms to promote sustainable forest management and achieve ecological, social and economic goals. FSC includes Forest Management (FM) and Chain of Custody (COC).

SAFEGUARDING EMPLOYEES' RIGHTS AND EMPOWERING TALENT GROWTH

Employee Benefits and Welfare

Employment System

The Group adheres to a people-oriented principle, attaches great importance to protecting employees' rights and interests and supporting their career development, strives to establish a sound and standardised employment and employee management system, and earnestly fulfils its responsibilities as an employer. The Group strictly complies with the *Labour Law of the People's Republic of China*, the *Labour Contract Law of the People's Republic of China* and other laws and regulations relating to labour and social security. The Group has formulated policies and systems such as the *Employee Manual*, the *Attendance and Leave Management System*, the *Recruitment Management System* and the *Promotion Management System*, which comprehensively cover various areas of human resources management, including employee compensation and benefits, recruitment and hiring, promotion and development, working hours, attendance and leave, and dismissal procedures. Through a well-established system of policies, the Group standardises day-to-day employee management, fosters harmonious and stable labour relations, and provides employees with a fair, regulated and secure working environment. As of the end of the Reporting Period, we had a total of 1,202 employees.

Equal Opportunity Recruitment

The Group strictly complies with the laws and regulations on equality and anti-discrimination in the countries and regions where it operates, and provides employees with equal employment opportunities and fair treatment in their careers. We are committed to respecting and safeguarding the legitimate rights and interests of every employee. During recruitment, we strictly stipulate that there will be no discrimination or differential treatment in hiring, promotion, or compensation on the basis of gender, age, place of origin, ethnicity, race, religion, disability, or any similar factor. As of the end of the Reporting Period, we employed 142 employees from ethnic minority groups and 60 foreign nationals, together accounting for 16.81% of our total workforce. Our male-to-female ratio is 1:1.04.

To further enhance the effectiveness and efficiency of our recruitment and to identify high-calibre talent aligned with the Group's development needs and role requirements, the Group has engaged professional third-party evaluation institutions in the recruitment and talent evaluation process. These institutions conduct systematic, professional, and comprehensive assessments of candidates, ensuring the quality of our talent from all perspectives. The evaluation system covers multiple core dimensions, including a comprehensive assessment of R&D capabilities for professional competence, personality assessments for personal qualities and job fit, and psychological risk factor assessments. It provides full coverage of areas such as thinking patterns, interpersonal skills, emotional stability, self-confidence, learning agility, and adaptability. Through scientific evaluation methods, it enables precise matching of people and positions, effectively improving recruitment efficiency and the stability of new hires, and building a high-calibre pool of professional talent for the Group's development.

SAFEGUARDING EMPLOYEES' RIGHTS AND EMPOWERING TALENT GROWTH

Welfare and Benefits

The Group is committed to providing employees with a comprehensive remuneration and benefits system. In addition to basic salary, the Group also offers a range of additional benefits. To safeguard employees' lawful rights and interests and to secure better benefits and development opportunities, the Group has lawfully established a labour union, which works together with the Company to organise various engagement activities and facilitate open communication and cooperation between employees and the enterprise.

When employees need to work overtime, the Group provides free dinners or meal allowances. To ease housing pressure for fresh graduates and other employees in need, the Group offers staff dormitories. Employees who do not live in the dormitories may receive transportation allowances based on the nature of their positions, demonstrating the Group's genuine care for their daily needs. The Group actively promotes family-friendly policies and supports employees in maintaining a healthy work-life balance. Male employees are entitled to 15 calendar days of paternity leave, subject to applicable national regulations. Female employees, in addition to enjoying statutory maternity leave and breastfeeding leave, may also apply for prenatal check-up leave in accordance with relevant regulations.

The Group also encourages employees to pursue diversified development and actively organises various exchange and interactive activities to further strengthen communication and collaboration among employees and foster a united and harmonious workplace atmosphere. We aim to enrich employees' leisure time and promote a healthy lifestyle that balances work and rest. The Group's factories are equipped with basketball courts, table tennis tables and other recreational facilities. We also work continuously with nearby professional sports venues to establish various sports clubs and regularly organise activities such as basketball games, badminton competitions and football matches to help employees balance work and life and maintain good physical and mental well-being.

The Group strongly supports a wide range of team-building activities, provides dedicated team-building leave, allocates special team-building funds, and actively promotes such initiatives to strengthen teamwork and foster a harmonious and stable corporate culture. The Group also regularly organises domestic and overseas themed travel activities for employees to further enhance team cohesion and unity. This year, the Group has planned and hosted a variety of enriching team-building and recreational activities for employees, including traditional cultural and festive activities such as the New Year's Day gala, Spring Festival red-envelope distribution, Lantern Festival celebration, Mid-Autumn Festival reunion, and Thanksgiving Day interaction, to carry forward and promote traditional customs. Dedicated team-building programs have also been organised specifically for management personnel to strengthen cohesion within the management team and foster an outstanding corporate culture aligned with the Group's development.

In addition, the Group places great importance on recognising employees' contributions and value. Through dedicated initiatives such as long-service awards and annual outstanding employee awards, the Group acknowledges employees' hard work and exceptional performance, boosts their enthusiasm and sense of belonging, further consolidates harmonious and stable labour relations, and promotes shared growth and mutually beneficial development between employees and the Group.

To further strengthen talent incentives and deepen the bond of shared development between employees and the Group, the Group plans to implement a dedicated share incentive scheme for our core team, including directors and senior management, as well as all outstanding employees. Through this incentive mechanism, the Group effectively enhances employees' sense of belonging and identification with the Group, fully unleashes their potential and initiative at work, and motivates all employees to continuously improve their performance and work together with the Group to achieve long-term, steady growth.

Labour Standards

The Group strictly complies with relevant labour laws and regulations, such as the *Labour Law of the People's Republic of China* and the *Law of the People's Republic of China on the Protection of Minors*. The Group strictly prohibits the employment of child labour and any form of forced labour, and has set out relevant rules in the *Employee Manual*. The original identification documents of successful candidates are checked at the time of employment to ensure compliance with the national labour law requirements. If someone working in the Group is under the age of 18 or has provided false information with regard to his/her age, the Group would terminate his/her employment at once and contact such employee's parents and/or the local government to take them back and bear all the costs.

The Group respects employees' rights and interests in freely choosing employment, resigning, taking rest, and other related matters. If an employee resigns for personal reasons, he/she shall complete the *Resignation Application Form* in advance and submit it to our Human Resources Department for approval. The Group must also comply with the national employment laws and pay the wages to employees who leave the Group. Furthermore, the Group has developed relevant rules for preventing forced labour with reference to market practices and does not force employees to work. The Group prepares production schedules periodically to prevent employees from working overtime and reviews its workflow from time to time. In the event that working overtime is necessary, an application shall be made to his/her direct supervisor. Employees who worked overtime may take time off afterwards according to relevant arrangements.

During the Reporting Period, there were no cases against the Group for violations of laws or regulations relating to hiring child labour or forced labour.

Health and Safety

Health and Safety Protection

As a firm focusing on medical device production, the Group has always regarded employees' workplace health and safety as a core management priority and recognises that workplace safety and employees' physical and mental well-being are directly related to the stable operation and long-term development of the Company. We strictly comply with the *Law of the People's Republic of China on Work Safety*, the *Law of the People's Republic of China on Prevention and Control of Occupational Diseases*, and other relevant laws and regulations, and have established the corresponding Environment, Occupational Health and Safety Department that is responsible for the overall management and control of occupational health and safety. In strict accordance with national laws and regulations and aligned with the Group's overall strategic development objectives, we have formulated relevant systems, including the *Occupational Health Management System*, the *Industrial Accident Management System*, and the *Labour Insurance Supplies Management System*, to build a comprehensive safety management framework. This enables us to safeguard employees' physical and mental well-being, prevent and control production and operational risks in all aspects, and strive to achieve a zero-accident management target.

SAFEGUARDING EMPLOYEES' RIGHTS AND EMPOWERING TALENT GROWTH

In terms of employee health protection, the Group arranges routine physical examinations for all employees every year and establishes employee health records. For positions with occupational hazards, pre-post, on-the-job, and off-post physical examinations for employees will be strictly conducted according to the corresponding regulatory requirements. The Group implements targeted prevention and control of occupational disease risks and aims to safeguard employees' health rights and interests throughout the entire process. In addition, the Group, according to the law, has purchased medical insurance for employees since they have joined the Group, covering in-patient, out-patient and Chinese medicine services. Moreover, the Group provides employees with additional insurance by purchasing supplementary commercial medical insurance, overseas travel insurance, and other types of commercial coverage to expand and strengthen protection, offer comprehensive additional protection for employees' work, travel, and daily medical needs, and build a solid foundation of defence for their health and safety.

Working Environment Maintenance

To continually improve employees' working environment and create a comfortable and safe workplace, the Group keeps its workplace ventilated by the combination of natural and mechanical ventilation. Air conditioning facilities are installed to dynamically maintain proper ventilation, with temperature and humidity kept within an appropriate range, thereby providing employees with comfortable and people-oriented working conditions. Core areas such as laboratories, production workshops, inspection workshops, and storage warehouses are managed by automated systems to ensure that ventilation meets relevant standards at all times. Dedicated pollutant treatment systems are installed to closely monitor and properly handle all types of pollutants arising throughout the production and operation processes, thereby eliminating potential environmental hazards and operational risks.

In terms of factory hygiene management, the Group has established a regular cleaning and vector control mechanism. Cleaning staff conduct daily, scheduled, comprehensive cleaning of public areas inside and outside the factory, surrounding green belts, and sanitary corners, and promptly remove stagnant water and debris to keep the factory area consistently clean and orderly. For key areas prone to mosquito breeding, the Engineering Department regularly arranges professional pest control services to implement vector control measures, protect workplace hygiene for employees down to the smallest details, and further reinforce the Group's workplace health and safety defence.

The Group's Songshan Lake Park has an environmental impact assessment and has passed the review. To maintain a standardised working environment and build a strong defence for safe operations, Songshan Lake Park has established an Environmental, Occupational Health and Safety Management Committee, led by the Environment, Occupational Health and Safety Department. Through the committee mechanism, the Department coordinates and efficiently advances environmental management, occupational health management, and production safety control across the Park, ensuring that all operations are compliant and risks are kept under control.

In terms of laboratory management, to fully ensure the safety and hygiene of the laboratory testing environment, safeguard the personal safety and health of laboratory personnel, ensure the authenticity and security of test data, maintain the stable operation of instruments and equipment, and standardise the classified storage and use of glass instruments and consumables, the Group has formulated a *Laboratory Management System*. This system sets out strict and clear requirements for entire laboratory workflows, operating procedures for instruments and equipment, and safety precautions, thereby strengthening accountability for laboratory operation and control via institutions and eliminating operational risks and potential environmental and hygiene hazards.

Occupational Disease Management and Prevention

The Group highly values employees' occupational disease prevention and control and full-process management, incorporates occupational disease prevention into the core occupational health and safety management framework, and has formulated regulations such as the *Occupational Health Management System* and *Warning Signs for Occupational Hazards in Workplaces*. These regulations clarify requirements regarding site control, risk warnings, and personal protection, thereby building a strong institutional line of defence against occupational diseases and effectively safeguarding the physical health of frontline employees and on-site employees.

In accordance with the provisions of the *Occupational Health Management System* of LifeTech, and to comprehensively protect employees from occupational disease hazards and clarify management responsibilities across positions, the Group implements a general manager responsibility system, under which the general manager takes overall responsibility for the Group's comprehensive occupational health management. Besides, a safety officer role has been established to drive the implementation of occupational disease prevention and control measures and occupational health management measures. The specific core responsibilities are as follows:

- Establish work safety management systems, emergency response plans, and organise drills;
- Identify, evaluate, implement tiered control, inspect and record the Group's work safety regularly;
- Facilitate the construction of safe and occupational disease protective facilities and implement prevention and control measures against occupational diseases;
- Organise work safety publicity, education and training, investigate work safety incidents, and stop and rectify non-compliant operations.

In addition, safety officers are responsible for providing employees in high-risk positions with occupational health and safety operation training and regularly inspecting whether personal protective equipment is worn properly, to ensure that all protective requirements are effectively implemented. For positions involving potential occupational hazards such as sterilisation, polishing and spot welding, the Group provides specialised protective equipment that meets national standards and continually conducts safety education and operational guidance to ensure that employees correctly wear and properly use all types of protective gear.

To strengthen risk alerts and on-site control, we have posted conspicuous safety warning marks and occupational hazard notices in dangerous operating areas of all types of equipment and at the workplace exposed to potential occupational hazards. These marks and notices specify risk types and protection requirements. We have fully equipped each site with the corresponding emergency supplies in accordance with relevant standards, building a solid foundation for on-site safety. In addition, the Group strictly implements equipment safety control requirements. All production equipment is installed with dedicated emergency stop switches to ensure that it can be shut down quickly in an emergency. Each piece of equipment is equipped with residual current devices for leakage protection. In the event of an abnormal electricity leak, they will automatically cut off the power to help prevent equipment failures and electrical safety incidents and provide employees with comprehensive protection for work safety.

The Group's Environment, Occupational Health and Safety Department will hire an independent third party to identify, analyse and test the occupational hazard factors of all posts every year. Test items include relevant chemical substances, production procedures and equipment. From the test results, it can be determined whether there is an occupational hazard in each post. In addition, the Company will provide pre-post, on-the-job, and off-post physical examinations and adequate training for employees working in posts with occupational hazards, and will provide qualified labour protection supplies.

The Group's occupational health evaluation is as follows:

Position	Occupational hazards	Protective facilities	Provision of protective equipment	Compliance evaluation
Sterilisation	Ethylene oxide	Sealing	Full-face gas mask	Pass
Laser welding	Laser radiation	Equipment with mask, fully ventilated workshop	Anti-laser goggles	Pass
Argon arc welding	Ultraviolet radiation, welding smoke	Equipment with mask, fully ventilated workshop	Welding goggles	Pass
Ultrasonic cleaning	Noise	Individually arranged, low-noise equipment	Protective earmuffs/ earplugs	Pass
Sandblasting	Noise, dust	Individually arranged, sealed equipment	Dust masks, earplugs	Pass
Chemical polishing	Methyl alcohol, acid fog, hydrogen fluoride	Fume hood, fully ventilated workshop	Half-face gas mask, protective gloves	Pass
Heat setting	High temperature	Fully ventilated workshop; equipment enclosure with thermal insulation materials	Anti-burn gloves	Pass

Work Injury

If an employee is unfortunately injured in the course of work, the Group will immediately activate its emergency response and promptly send the injured employee to a qualified medical institution for treatment. The Group will fully cover all upfront medical expenses related to the employee's work injury treatment and will make every effort to ensure that the injured employee receives timely and effective medical care. Moreover, the department where the injured employee works shall promptly review the course of the accident, submit an *Accident Investigation Report* to the Safety Management Department in a timely manner, and thoroughly verify the cause and details of the accident. Safety officers shall strictly comply with the statutory time limits and proactively submit an application for work injury determination to the Social Security Department, ensuring that the work injury handling process is compliant and efficient. After the recovery of the injured employee, the Group will, based on the employee's post-recovery physical condition, appropriately assign a suitable position and organise dedicated pre-post safety training. After the employee passes the assessment, the Group will arrange for a smooth return to work, giving full consideration to both the employee's health and employment rights.

In the past three years, the Group has had no cases of work injury or death.

Work Safety Education Training

The Group complies with relevant laws and regulations, such as the *Law of the People's Republic of China on Work Safety*, the *Law of the People's Republic of China on Prevention and Control of Occupational Diseases*, and the *Fire Protection Law of the People's Republic of China*, and regards work safety training as an important measure for implementing the policy of "Safety First, Prevention Oriented, and Comprehensive Governance". The Group has formulated the *Safety Education Training System* to standardise the Group's work safety training.

Safety training of the Group is divided into three parts as follows:

Employee type	Training requirements
Safety officer	o Relevant employees may take up positions only after acquiring the safety qualification certificates certified by the supervision and administration department of work safety.
Employee	o New employees shall take their positions after accepting the three-level safety education training and passing the examination. Three-level safety education is arranged as follows: Company: Safety officers are responsible for training, including courses of fire safety, occupational health safety, and safety regulations of the Group; Department: The head of the department is responsible for training on on-site evacuation, the use of safety equipment, and the work safety status of the department; Team: The team leader introduces production characteristics of posts, the use of personal protective equipment, and other protective measures. o Special operation staff shall take their positions after accepting specific safety operation training and obtaining the corresponding qualification certificates.
Other staff	o In case of transferring or leaving posts for over six months, employees concerned shall take part in safety training organised by the department and the team, and qualified ones can work in the new positions; o When new processes or new devices come into use, safety training shall be arranged for the relevant employees based on the characteristics of new processes and devices; o During high-risk overhaul projects, raise safety requirements for construction workers and verify that all safety measures are implemented.

The Group organised a total of three emergency evacuation drills during the Reporting Period. The Group conducted regular on-site emergency treatment drills according to the operational risks of each position. Department representatives also received training in emergency first aid.

During the Reporting Period, there was no violation of laws and regulations by the Group in relation to health and safety. No cases resulted in fines or prosecutions against the Group.

SAFEGUARDING EMPLOYEES' RIGHTS AND EMPOWERING TALENT GROWTH

Talent Management and Development

Training System

LifeTech focuses on employee development, providing comprehensive and professional vocational training to fully unlock employees' strengths and potential. We have established a talent training system, covering management training, on-the-job training, and new employee training. We continue to refine our internal lecturer system. The Group provides employees with internal training and external training in accordance with the formulated *Training Management System*.

Training form and arrangement	Training arrangement
Internal training	Internal training is provided by the Group's internal lecturers, and the covering training on company systems, training for new employees, induction training for operational employees, and professional skills training.
External training	External training consists of two forms: sending employees to external training programmes and inviting external lecturers. After the external training, the trained employees communicate with other colleagues through sharing sessions and other methods.
Self-learning	Alongside work arrangements, employees are encouraged to learn from the *Online Lecture on Peripheral Artery Disease* series of training courses organised by the Group, or enhance professional and general knowledge via the internet, external institutions, and other channels in their spare time. LifeTech encourages employees to achieve professional improvement through self-learning.

In terms of internal training, the Group has established an internal lecturer system, drawing on senior management, key technical personnel, and experienced employees within the Group to form an internal lecturer team. Based on employees' actual job needs and the Group's operational and management standards, this team carries out regular, structured internal training. The training covers all core modules. For new employees, we offer foundational training on company systems and induction projects to help them quickly become familiar with the corporate culture, job responsibilities, and company rules and requirements. For front-line operational employees, we deliver targeted pre-post and standard operational training to reinforce standardised work procedures and safety awareness. For employees in technical, managerial and other roles, we provide professional skills enhancement, business capability development, and management thinking training. In this way, we fully address the development needs of employees at different levels and in different positions, helping them rapidly enhance their job competence and achieve shared growth for both individuals and the Group.

In terms of external training, the Group has established the *External Training Management System*. The Group classifies external training into two forms: sending employees to external training programmes and inviting external lecturers. The first involves sending employees by the Group, aligned with the Group's overall development strategies or position requirements, to attend relevant training and advanced-study programmes at external professional institutions. The second involves inviting experienced external lecturers and industry experts to deliver themed training sessions within the Group. We fully take into account the needs of each department. Where external training involves specialised scenarios such as tackling core technical challenges or conducting cutting-edge academic research, the relevant department may independently submit a training application. The corresponding training may only be organised after it has passed rigorous review and approval by the Human Resources Department. We actively promote the internal sharing and practical application of outcomes from all types of external training. We aim to actively foster knowledge sharing and joint capability enhancement, and continually strengthen the overall professional competence of the Group's talent pool.

In terms of self-learning, the Group continually updates and enriches the *Online Lecture on Peripheral Artery Disease* series of training courses to provide employees with ample supporting resources for independent study. The course topics include basic disease knowledge, consensus guidelines, detailed introduction to the full range of peripheral products, treatment strategies and technical points for complex aortic lesions, clinical trial-related regulations, and the application of office software. There are 241 courses for colleagues at different stages and with different needs to learn online and improve their professional skills. Employees may schedule courses according to their own time and learning progress. They may take a course flexibly. The learning progress tracking and feedback mechanism provided by the platform further motivates employees to participate actively. Through the platform, new employees can learn the basics, quickly integrate into the team, and acquire the necessary professional skills; senior employees can choose more advanced courses, such as expert seminars, to further enhance their professional capabilities.

During the Reporting Period, we offered a total of 32,060.30 training hours, covering 1,142 employees across the Group.

SAFEGUARDING EMPLOYEES' RIGHTS AND EMPOWERING TALENT GROWTH

Promotion Pathway

To support employees' long-term career development and fully unlock their potential and motivation, the Group has established a dual-channel development and promotion framework. Differentiated assessment mechanisms tailored to job characteristics have been set up for non-managerial employees, operational employees, and managerial employees, ensuring that employees in all types of positions have clear career and promotion paths. The entire employee promotion process is coordinated and overseen by the Human Resources Department together with the Group's senior management, with strict control over assessment and promotion standards. The specific assessment and management measures are as follows:

Assessment item	Assessment content	Assessment methods
Overall competence	Work attitude, professional ethics, and identification with the Company	Questionnaires, employee interviews
Business capability	Job knowledge, professional skills, English, software applications, etc.	Written tests, interviews, practical assessments, and work presentations
Management capability	Leadership, communication, and collaboration and management skills	Case studies, 360-degree assessments, and work presentations

For non-managerial employees, we have established five position grades: Junior, Intermediate, Senior, Advanced, and Expert. Employees may adjust their position grade through the annually scheduled grade evaluation, with reference to their annual performance appraisal. Upon completion of the probationary period, new hires receive their initial grading according to this standard. For operational employees, position grade is determined by a comprehensive assessment of the depth and breadth of their skills, the scarcity of those skills, and the qualification rate of the products for which they are responsible. For managerial employees, a multi-level promotion path of "Supervisor - Manager - Director - Vice President" has been established. The Company also actively provides managerial employees with management skills training to help them gain greater rewards by creating more value for the Company.

Praise and Incentive

LifeTech encourages employees to actively innovate and pursue the spirit of pioneering and dedication. Therefore, we set up annual awards, special awards, and other awards, and reward employees with praise, cash, or other forms of reward according to the actual situation. Recipients of such awards also include outstanding employees, annual sales stars, special award winners, and patent-related award winners. A reasonable suggestion award is set up to encourage employees to put forward reasonable suggestions on daily production operations, management, quality and technology, and to reward employees whose suggestions are adopted within the year and result in good outcomes.

PRACTISING GREEN OPERATIONS AND JOINING HANDS TO PURSUE LOW-CARBON DEVELOPMENT

The Group fully complies with the environmental protection laws and regulations applicable in the jurisdictions where it operates, including but not limited to the *Environmental Protection Law of the People's Republic of China*, the *Law of the People's Republic of China on Environmental Impact Appraisal*, and the *Law of the People's Republic of China on Promotion of Cleaner Production*, and has formulated and implemented an *Environmental Management System*. The Group continues to review the environmental requirements for new development projects through established procedures. When an incident occurs at assets under our operational control, we classify, record, and report it in a timely manner in accordance with relevant internal procedures to facilitate a rapid response and optimal resolution of the incident.

During the Reporting Period, there was no violation of laws and regulations by the Group in relation to emissions and the environment. No cases resulted in fines or prosecutions against the Group.

The Group strives to integrate environmental protection throughout the entire product life cycle, including product development, design, production, and transportation. At the product design stage, we design products with a longer service life in order to reduce waste emissions. In the research and development (R&D) process, we use environmentally friendly materials, efficient technologies, and non-toxic, harmless materials such as degradable poly (lactic acid), iron, and raw materials that comply with RoHS standards, thereby reducing environmental pollution. At the production stage, we adopt more environmentally friendly production processes and build efficient production chains to reduce waste generation, improve production efficiency, and lower energy consumption. At the transportation stage, we choose more efficient modes of transport and cooperate with logistics suppliers that hold environmental qualifications.

The Songshan Lake Park includes office areas, factories, and other work areas, as well as kitchens, canteens, staff dormitories, infrastructure, and other living facilities and logistics support areas. There are two staff dormitory buildings in the Songshan Lake Park, which are managed by the Group's Administrative Department. Accordingly, the domestic water consumption of employees living in these dormitories has some impact on the Group's overall water use.

PRACTISING GREEN OPERATIONS AND JOINING HANDS TO PURSUE LOW-CARBON DEVELOPMENT

Energy Efficiency and Carbon Emissions Management

The Group continually reviews, collects, and reports greenhouse gas (GHG) emissions (or "carbon emissions") generated by its operations, and quantifies them with reference to and in accordance with the *How to Prepare an ESG Report – Appendix 2: Reporting Guidance on Environmental KPIs* issued by the Stock Exchange, and the guidelines issued by the National Development and Reform Commission of China. Our carbon emissions mainly come from Scope 2 indirect GHG emissions generated by purchased electricity, followed by Scope 1 direct GHG emissions from stationary sources and mobile fuel combustion. In addition, we continue to advance the identification of categories, data collection, and quantitative disclosure of value chain GHG emissions under Scope 3. We mainly drive GHG emissions reduction through fuel and energy management initiatives, in order to achieve our low-carbon and green sustainable development goals.

The Group focuses on the main business and production processes that account for the bulk of electricity consumption at its factories, and upgrades or phases out certain outdated and energy-intensive equipment. In the office areas, we have adjusted the operating hours and temperature settings of air conditioners to reduce electricity consumption. We place great emphasis on reducing resource waste during production and are committed to creating a work environment that conserves natural resources and lowers energy consumption. We have formulated the *Energy Management Control Process* and adopted the following approaches for different types of resources:

Resource type	Treatment methods
Oil	• Each department reasonably uses oil products according to the requirements of equipment lubricating oil and waste oil recovery; • All replaced waste oil is uniformly reclaimed and handled by the user department and the administrative department; • Vehicles are maintained regularly to keep oil consumption within a normal range.
Electricity	• In the ordinary course of business, gradually replace office lights with brighter, more energy-efficient LED lights; • The lighting system at the Shenzhen Headquarters relies on LED lights. Songshan Lake Park is furnished with LED lights; • Regularly maintain, service, and inspect electrical facilities; • Reduce the energy consumption of the energy-intensive air-conditioning systems in clean rooms by using recycled water for cooling; • Purchase electric vehicles for the maintenance staff of the Engineering Department in case of any emergency repair tasks.

Gas Emissions Management

The Group's gas emissions include nitrogen oxides, sulfur oxides, and respirable suspended particulates generated by vehicle fuel combustion and the use of natural gas in kitchens. In accordance with the *Environmental Management System*, the Group continues to strengthen vehicle maintenance and servicing to ensure compliance with emission standards; limit vehicle usage and promote green travel; and replace outdated kitchen equipment promptly to improve fuel efficiency, avoid incomplete combustion, and minimise exhaust gas emissions.

The polishing process for the Group's filters and covered stents generates volatile organic compounds (VOCs), such as benzene, cyclic aromatic hydrocarbons, and aromatic hydrocarbons. These substances pose a threat to the environment and to the health of nearby residents. Therefore, the Group has removed the VOCs and reduced pollution by absorption and dilute phosphoric acid catalysis.

The Group has engaged a qualified third-party manufacturer to provide solutions for the Group's production and laboratory-sourced exhaust gases. All exhaust gases generated on the laboratory floor of LifeTech Shenzhen's building are collected, segregated, and treated through facilities and discharged after meeting applicable standards. Specifically, organic exhaust gas is collected through the pipeline and then adsorbed by activated carbon in the exhaust gas treatment facility; acid gas is collected through the pipeline and then neutralised by alkali water sprayed in the exhaust gas treatment facility; the gas generated in the production is collected through the pipeline and then treated by UV photolysis and water spraying process in the exhaust gas treatment facility.

The Group's Songshan Lake Park produces polishing exhaust gas, laminating heat treatment exhaust gas, sterilising exhaust gas, and other exhaust gases during the process of product production, sterilisation, and packaging. We have adopted different treatment methods for different exhaust gases. Chemical polishing, laminating heat treatment exhaust gas: After being collected through fume hoods and sealed pipelines, it is treated within an "alkali water spray + secondary activated carbon adsorption" treatment system and emissions at high altitudes with compliance. The exhaust gas from the sterilisation process is introduced into a "dilute phosphoric acid aqueous solution absorption + water spray scrubber" treatment system by a vacuum pump for treatment before being discharged at high altitude. The processing process is as follows:



PRACTISING GREEN OPERATIONS AND JOINING HANDS TO PURSUE LOW-CARBON DEVELOPMENT

The exhaust gas treatment facilities are linked to the waste production process equipment to ensure that the emissions generated are discharged after the treatment meets the standards. At the same time, in order to ensure the standardisation of the operation of the exhaust gas treatment equipment, the Group also invites a third-party quality inspection institution to conduct operation training for employees to ensure that equipment failures can be handled in a timely and correct manner.

The Group also requires the Administrative Department to regularly and continually monitor exhaust gases generated from the process of all production and experiments, making sure the emissions meet the relevant standards. If any unusual emissions have been identified, the Group will shut down the source of such emissions temporarily and report the incident to the relevant departments and the environmental authorities.

Water Resource Management

The Group attaches great importance to water conservation, adheres the concept of scientific water use, actively promotes and encourages water saving, and is committed to building a resource-efficient enterprise. All of our water is supplied through the municipal network, so there are no issues with securing suitable water sources. In accordance with the *Environmental Management System*, the Group conducts rainwater and sewage water diversion and manages the industrial wastewater, domestic sewage, and rainwater in a separate and systematic manner.

Wastewater type	Processing methods
Industrial wastewater	• Common industrial wastewater, like general test wastewater and clean water, is processed directly by being discharged into a sewage treatment plant through municipal pipes. • Chemical effluent and other wastewater containing hazardous substances are collected and deposited in the designated hazardous waste warehouse and then regularly delivered to the qualified processing unit for treatment.
Domestic sewage	• Domestic sewage mainly refers to wastewater discharged from toilets and pantries. All the domestic sewage is discharged to the municipal sewage pipes and enters the Nanshan Sewage Treatment Plant for treatment upon the completion of the pre-treatment through a septic tank.
Rainwater	• Rainwater is directly discharged outside by independent pipes.

Industrial Wastewater

The Group's Songshan Lake Park factory is equipped with wastewater treatment facilities for ultrasonic degreasing cleaning wastewater and laboratory glassware washing wastewater. The wastewater from the Songshan Lake Park factory is discharged into the municipal sewage interception pipe after being processed by the self-built wastewater treatment station to meet the more stringent limits between the Level III, Period II standard set out in the *Discharge Limits of Water Pollutants* of Guangdong Province (DB44/26-2001) and the Class B standard set out in the *Wastewater Quality Standards for Discharge to Municipal Sewers* (GB/T 31962-2015), and then introduced into the Dalang Songshan Lake Southern Sewage Treatment Plant in Dongguan City for advanced treatment. The drainage of the Dalang Songshan Lake Southern Sewage Treatment Plant in Dongguan City is subject to the stricter value of the Class 1A standard of the *Discharge Standard of Pollutants for Municipal Wastewater Treatment Plant* (GB18918-2002) and the Level I, Period II standard set out in the *Discharge Limits of Water Pollutants* of Guangdong Province (DB44/26-2001).

Domestic Sewage

Domestic sewage from the Group's Songshan Lake Park is discharged into the municipal sewage interception pipe after being pre-treated to meet the more stringent limits between the Level III, Period II standard set out in the *Discharge Limits of Water Pollutants* of Guangdong Province (DB44/26-2001) and the Class B standard set out in the *Wastewater Quality Standards for Discharge to Municipal Sewers* (GB/T 31962-2015), which are then introduced into the Dalang Songshan Lake Southern Sewage Treatment Plant in Dongguan City for advanced treatment.

Rainwater

The Group's Songshan Lake Park adopts a rainwater-sewage diversion system. Rainwater and sewage are collected and treated separately. Rainwater is collected through the factory rainwater pipes and discharged into the municipal rainwater pipeline network, which is then discharged into the Songmushan Reservoir.

In addition, the Group collects the tail water from the factory's pure water system for use in cooling cleanroom air-conditioning units, thereby recovering and reusing water resources. Water meters are installed in production and office areas to measure water consumption, and monthly water usage is recorded. In case of abnormalities, causes are investigated. Measures are taken to resolve the abnormalities. The Administrative Department shall regularly check water usage. If faucets or valves are found to have any damage, they will be repaired and replaced in a timely manner.

PRACTISING GREEN OPERATIONS AND JOINING HANDS TO PURSUE LOW-CARBON DEVELOPMENT

Waste and Recycled Materials Management

The Group uniformly handles waste generated during the production process in accordance with the *Environmental Management System*.

Waste classification	Processing methods
Non-hazardous waste	• The Administrative Department is responsible for contacting qualified disposal service providers to recover and process recyclable waste; and • Non-recyclable domestic waste is collected and transported by the environmental authorities.
Hazardous waste	• All hazardous waste shall be collected upon classification pursuant to the *List of Hazardous Waste*; • Hazardous waste generated by the production departments shall be stored in designated hazardous waste bins with lids and the *Hazardous Waste Handover Form* shall be completed; and • Hazardous waste shall be regularly delivered to qualified organisations for treatment.

The Group endeavours to reduce both the hazardous and non-hazardous wastes it produces, and works with qualified parties and partners to reuse or recycle whenever possible. All wastes are managed according to the waste management hierarchy (i.e. prevention, reduction, reuse, recycling, replacement, treatment, and disposal). LifeTech seeks to avoid the use of hazardous materials and replace them with alternatives wherever possible. All hazardous and non-hazardous wastes are managed in accordance with local regulations, collected by licensed collectors, or sold for recycling.

The Group operates a smart office, adopting an electronic approval process, a card-swiping system for printing in order to control the number of printouts, and advocating the use of shared files and soft copies in order to minimise paper documents and waste. The office automation system fully arranges and effectively transmits the information through the information system, so that the enterprise's resources can be reasonably allocated and utilised in purchase, storage, production, sales, manpower, financial, material and other aspects. The production site manufacturing system sets traceability of the manufacturing process, paperless production, and digitalisation as its core objectives, and covers business management informatisation, such as production planning, basic personnel information, basic information on equipment and tools, product process routes, and the traceability of materials, semi-finished products, and finished products throughout the manufacturing process.

Management of Packaging Materials

In terms of managing and recycling packaging materials and consumables, the Group upholds the principle of green conservation and resource circularity, and exercises strict control over material use. Except for certain core production processes that, due to product-specific cleanliness requirements, must use single-use dedicated packaging materials, all other processes have fully adopted a packaging materials reuse and recycling mechanism. This mechanism covers the entire workflow, including warehouse storage, in-plant material flows, transfer of semi-finished products, and routine material allocation. By standardising collection, ensuring proper storage, and enabling repeated use, the Group effectively reduces the consumption of packaging materials and the generation of waste, fulfils environmental requirements regarding energy conservation and emissions reduction, and supports the establishment of a green production system.

Environment and Natural Resources

Biodiversity Conservation

The Group fully recognises that ecosystems are the fundamental environment on which humanity depends and that new factory construction and operations may impact surrounding areas. Accordingly, the Group consistently follows an environmental management approach of green construction and compliant operation, and strictly upholds the baseline requirements for environmental protection. Whether a project involves new construction, reconstruction, or expansion, the Group conducts a comprehensive environmental impact assessment in advance at the design and planning stage. Throughout the entire construction cycle, the Group carries out design and construction in strict accordance with the environmental impact assessment approval requirements and eliminates any non-compliant construction activities. After project construction is completed, the Group also organises completion acceptance strictly in line with the relevant environmental impact assessment standards and requirements. Only once the project has passed acceptance and all environmental protection indicators meet the required standards will it be formally confirmed, delivered, and put into operation.

The LifeTech Shenzhen's research and development laboratory, which has been in use since 2018, was built in accordance with design plans approved by the local environmental protection, water affairs, and other relevant government departments. The Songshan Lake Park of LifeTech, which has been in use since 2023, was also constructed in accordance with design plans approved by the local environmental protection, water affairs, and other relevant government departments in Dongguan City. These facilities comprehensively safeguard employee health and safety while minimising the impact of construction on the surrounding environment.

PRACTISING GREEN OPERATIONS AND JOINING HANDS TO PURSUE LOW-CARBON DEVELOPMENT

Responding to Climate Change

Governance

The Group actively addresses climate change in response to *China's National Climate Change Programme*. The Group will continue to implement all existing energy-saving and emission-reduction measures, continually quantify carbon emissions, closely monitor the latest emission-reduction technologies, and minimise unnecessary transportation to control greenhouse gas emissions.

The Group has integrated climate change governance into the ESG governance framework and established a climate change response mechanism led by the Board of Directors, overseen by the ESG Committee, implemented by the ESG Taskforce, and supported by relevant departments. We regularly coordinate and consolidate updates to ESG-related policies and systems, promote the identification and analysis of climate-related risks, provide guidance on practical actions to address climate change, and ensure that climate change governance is carried out smoothly and effectively. For details of the ESG governance structure, please refer to the section "ESG Governance Structure".

We ensure that the ESG governance structure has the requisite experience and capabilities. For details of the Board of Directors, please refer to the "Corporate Governance Report" in the 2025 Annual Report. To continually enhance the Board members' capabilities in sustainability governance, we regularly engage professional ESG consultants to deliver training on topics such as sustainability regulatory requirements, climate change and carbon neutrality pathway planning. This supports the Company in identifying climate-related risks and opportunities, formulating response strategies, and equipping the ESG governance structure with the necessary expertise to effectively discharge ESG and climate-related governance responsibilities.

Strategy

With reference to the disclosure methodology and recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) framework, the Group has defined the management direction for addressing climate change, identified risks through the annual reporting process, and assessed the time horizons of potential impacts. The impacts are categorised as short term (<2 years), medium term (3–5 years), and medium to long term (>5 years). We plan to update the climate-related risk assessment results annually, incorporate them into our business strategy, and report regularly to the management, the Board, stakeholders, and the public. The Group has initially identified a range of climate-related risks and opportunities associated with our core business, assets, and operations. At present, the identified climate-related risks and opportunities have not had a significant impact on our business growth. Nevertheless, we are actively responding to the latest regulatory requirements and making early preparations, including professional training, readiness for disclosure work, and collaboration with external advisors, to ensure we have robust capabilities for climate-related information disclosure and to enhance the transparency and reliability of our disclosures.

In view of the Stock Exchange's relief arrangements (including (i) being unable to obtain reasonable information without undue costs or efforts ("**Reasonable Information Relief**"), (ii) not having the skills, capabilities or resources to provide the quantitative information ("**Capabilities Relief**"), and (iii) the current or anticipated financial effects of the climate-related risks or opportunity identified cannot be separately identified or would be so uncertain that the estimated effects is not useful ("**Financial Effects Relief**")), the Report does not, for the time being, disclose detailed information on financial effects, but focuses primarily on qualitative descriptions. In addition, we have not yet put in place a climate-related transition plan. We are committed to continually enhancing our related capabilities and will progressively improve our disclosures in future reports.

Risk types	Term	Specific circumstances	Measures	Financial effects
Physical risk				
Acute risk	*Short term*	Potential related emergencies (damage to production facilities and disruption of supply chains) due to natural disasters/ extreme weather (typhoons, heat waves, floods, cold weather)	• Pay close attention to weather conditions, send early warning messages to employees, plants and offices in response to extreme weather, and implement staggered production when necessary • Regularly inspect the operating environment of the plant and carry out safety checks on wind, water, electricity, etc. to eliminate potential hazards in a timely manner • Enhance supply chain contingency by continuously establishing back-up suppliers and actively developing localised suppliers • Prepare *Safety Emergency Plan* and *Environmental Emergency Plan* according to the characteristics of unexpected climate in the operation area, file for record accordingly and organise the drills • Fully consider the risk of urban flooding caused by extreme rainfall during the project construction phase, raise the foundation height, and equip emergency drainage facilities	The office premises, production plants, and equipment and facilities may be affected, potentially leading to damage, which could increase the Group's operational maintenance costs and reduce production efficiency

PRACTISING GREEN OPERATIONS AND JOINING HANDS TO PURSUE LOW-CARBON DEVELOPMENT

Risk types	Term	Specific circumstances	Measures	Financial effects
Physical risk				
Long-term risk	*Medium to long term*	The plant is in a water-stressed or water-scarce dry area, which poses a threat to the manufacturing process; Infrastructure in areas threatened by rising sea levels from climate change; Prolonged high temperatures adversely affect employees' health	• Use cloud servers to store and back up data and information, and regularly verify their functionality • Conduct forward-looking risk identification and assessment of long-term climate risks, and incorporate them into the selection criteria for plant sites • Mitigate the impact of high temperatures by equipping offices and production workshops with air conditioning and providing employees with heatstroke-prevention medication	The office premises, production plants, and equipment facilities may be affected, potentially leading to damage, which could increase the Group's operational maintenance costs and reduce production efficiency
Regulatory risk	*Medium to long term*	National and provincial environmental policies and laws have been changed and tightened; The medical device industry and manufacturing industry have fully implemented low-carbon policies	• Strengthen communication with regulatory authorities and institutions, promptly understand and strictly comply with changes in relevant regulatory laws and regulations, and ensure the compliance of products and services • Continuously pay attention to the dynamics of national laws and regulations and systems related to climate change • Continue to promote energy saving and consumption reduction measures to reduce greenhouse gas emissions	The increased regulatory requirements related to business operations have led to higher costs for the Group in terms of compliance operations and plant emission control; The increased ESG disclosure requirements have resulted in higher compliance information disclosure costs for the Group

Risk types	Term	Specific circumstances	Measures	Financial effects
Transition risk				
Technology risk	Medium term	The medical device industry and manufacturing sector continue to increase green requirements for products and services	• Continuously integrate the concept of energy conservation and emission reduction into product planning, such as using non-hazardous and harmless materials, adopting efficient production methods, and utilising energy-saving labeled equipment for production activities	The increased green requirements for products and services have led to higher research and development costs and increased procurement costs for environmentally friendly materials and equipment for the Group
Market change risk	*Short term*	The value of resources such as electricity, fuel, and water fluctuates due to the impact of climate change	• Plan efficient production lines for new plants, prioritise the use of energy-saving equipment, and strengthen equipment maintenance to reduce unnecessary energy consumption • Install rainwater recycling and reuse systems in new plant to reduce unnecessary water resource consumption • Upgrade old equipment, enhance maintenance of ventilation and exhaust facilities, and install additional waste gas and wastewater treatment facilities to reduce pollutant emissions • Enhance publicity and management of energy saving and emission reduction	The fluctuation in the value of purchased resources has led to an increase in the Group's cost of procurement of resources, and an increase in the cost of procurement and construction of new equipment and production lines

PRACTISING GREEN OPERATIONS AND JOINING HANDS TO PURSUE LOW-CARBON DEVELOPMENT

Risk types	Term	Specific circumstances	Measures	Financial effects
Transition risk				
Reputation risk	*Long term*	Users' attention to corporate social responsibility; Poor performance and negative news on environmental protection and climate change could impact the Group's reputation	• Focus on the disclosure requirements related to sustainable development and climate change, and optimising the channels for external communication of corporate social responsibility on the basis of ensuring compliance • Actively fulfill corporate social responsibility to further enhance brand image • Proactively carry out climate risk identification work and proactively disclose measures and achievements in addressing climate change	Corporations need to fulfill social responsibilities and participate in environmental protection initiatives, leading to an increase in the Group's investment in social contributions, ESG governance and disclosure, and environmental protection

Opportunity category	Measures	Financial effects
Energy efficiency	Align with the national dual-carbon and energy-efficiency targets, gradually complete the green and low-carbon transition of the energy mix, and increase the share of renewable and clean energy	Enterprises focus on managing energy use, improving energy efficiency and reducing operating costs
Resource efficiency	Adopt more efficient operating models to improve resource efficiency, reduce emissions, practice sustainable development, and realise a circular economy	Enterprises focus on managing resource use to reduce product manufacturing and operating costs
Adaptability	Proactively plan for green and low-carbon development as domestic and international climate change policies become increasingly well developed, and enhance enterprises' ability to adapt to new market policies and legal requirements	Enterprises closely monitor policy changes, raise their information disclosure standards ahead of time, and reduce the costs arising from compliance penalties

Risk Management

The Group has incorporated climate risk identification and control into its Risk Management System and ESG System, with the Board of Directors serving as the highest risk-responsible body, accountable for the identification, prevention, and control of ESG risks. For details, please refer to the section titled "Corporate Governance and Risk Management." We will continue to proactively identify potential risks, formulate corresponding risk prevention measures and response plans, and regularly report risk management and control matters to the Board of Directors, seeking its opinions and guidance.

Metrics and Targets

The Group is committed to continuously enhancing the transparency and effectiveness of its climate change response through quantitative indicators. The Report discloses key climate-related environmental indicators, including energy consumption and intensity, greenhouse gas emissions and intensity, among others. For details, please refer to the section "KPI Overview." In addition, the Group has set qualitative and quantitative targets for greenhouse gas emissions and conducts annual performance reviews.

Stage	Targets	Key tasks
Stage I 2024-2030	Carbon peaking: Capacity building and emission reduction	• Formulate and commit to emission reduction targets and visions in line with the national "dual carbon" rules • Formulate carbon emission reduction plans and action plans under the background of carbon peaking, improve the efficiency of core products, reduce emissions in green supply chains, and build energy management centres
Stage II 2031-2050	Carbon neutrality: Overall capacity building, continual carbon reduction	• Set continuous carbon emission reduction targets under the background of carbon neutrality • Formulate carbon emission reduction plans and action plans under the background of carbon neutrality • Implement various carbon emission reduction tasks according to the plans
Stage III 2050	Zero-carbon products	• Achieve carbon neutrality in the ongoing operation and maintenance of the Board of Directors of LifeTech • Achieve zero carbon emissions throughout the entire lifecycle of all products

PRACTISING GREEN OPERATIONS AND JOINING HANDS TO PURSUE LOW-CARBON DEVELOPMENT

Environmental indicators	Targets	Achievements in 2025
GHG emissions	Based on a greenhouse gas emissions intensity (Scope 1 and Scope 2) of 0.2 tonnes of CO_2-e/m^2 in 2024, we aim to reduce this intensity by 5% by 2030.	In progress

During the Reporting Period, the Group optimised the HVAC system of the clean workshop in the plant area, with an investment of approximately RMB 10,000. In view of the Stock Exchange's relief arrangements (including Reasonable Information Relief and Capabilities Relief), the Report does not disclose cross-industry indicators, industry-specific indicators and the like. In addition, we hereby make a negative statement regarding internal carbon pricing and remuneration. The Group is committed to continuously enhancing the relevant capabilities and will progressively improve related disclosures in future reports.

FOCUSING ON SOCIAL NEEDS AND ENGAGING IN PUBLIC WELFARE INITIATIVES

LifeTech, as a leading medical technology corporation in China, actively takes its social responsibility to perform its obligation of being a corporate citizen. We work in medical technologies and join hands with medical institutions, industrial associations, experts and doctors to stimulate the implementation of "Access To Healthcare". Since the establishment in 1999, we have saved approximately 2.3 million patients' lives in total in over 120 countries.

Development Promotion on Healthcare Industry

The Group takes the initiative to engage in setting professional standards, holding industry conferences, writing books and paper publishing, in the field of medical technologies, and injecting power into the international standard and cutting-edge research of the medical industry.

We were not only engaged in the formulation of international standards *ISO/WD22679 Cardiovascular implants - Cardiac occluders* and *ISO/TS17137 Biological evaluation of medical devices - part 2 standard guide for absorbable metals*, but also the industrial standards *YY/T1533-2017 Cardiovascular implants - Cardiac occluders, YY/T1449.3-2016 Cardiovascular implants - Artificial heart valve Part III: Transcatheter Implantable Artificial Heart Valve, YY/T 0663.3-2016 Cardiovascular implants - Endovascular devices Part III: Vena Cava Filter*, acting as the main drafter, to lay a foundation for the regulation and standardisation of the industry.

We positively provide funds to and join in the world-leading and prestigious industrial conferences, both at home and abroad, including the congenital, structural and valvar heart disease interventions conference held in Frankfurt, Germany (CSI), the China Interventional Therapeutics (CIT), the Transcatheter Cardiovascular Therapeutics (TCT), The Leipzig Interventional Course (LINC), the Latin American Society of Interventional Cardiology (SOLACI - CACI) and other international academic conferences, as well as the South China International Congress of Cardiology (SCC), the China Southern Endovascular Congress (SEC), the China Endovascular Course (CEC) and other domestic academic conferences, contributing to the world's medical development and communication.

We participated in the compilation of scholarly monographs, such as *Bioresorbable scaffold-from basic to clinical application, An introduction to materials in medicine (《醫用材料概論》)* and *Toxicity and Pathology - Practical methods and techniques (《毒性病理學-實用方法與技術》)*, and published over 10 Science Citation Index (SCI) papers, providing basic theory and practical experience for doctors all over the world.

FOCUSING ON SOCIAL NEEDS AND ENGAGING IN PUBLIC WELFARE INITIATIVES

Power Channelling of Medical Equipment Enterprise

The Group pays attention to domestic and overseas charity activities concerning medical treatment and popularises medical knowledge through social media. The medical devices, materials and funds are also provided for patient treatment, public welfare diagnosis and treatment and monographic studies to show doctors' benevolence and deliver corporate strength.

An official WeChat public account is usually used to publish different kinds of popular science from time to time, so as to introduce the cause, treatment and relevant device application of cardiovascular diseases. This can raise public awareness of disease prevention and advocate a healthy lifestyle. We have attended *Approaching Science* hosted by China Central Television, a science program, to show the audience how to "patch a hole in the heart".

We provide backups to countries and regions that have poor medical technologies, including the donation of congenital heart disease occluder for the diagnosed patients, free professional healthcare service to those in need, and performing interventional occlusions for congenital heart disease for pediatric patients from poor families.

Technical Support to Grassroots Hospitals

As a professional enterprise deeply engaged in the medical device sector, LifeTech supports the enhancement of primary healthcare technologies, promotes the balanced development of medical resources, practices corporate social responsibility, and fulfills its duties as an industry leader. During the Reporting Period, LifeTech, together with local health authorities, carried out a free congenital heart disease screening charity program in Ningnan County, Xichang City, Sichuan Province. More than 1,000 children were screened, and through professional diagnostic methods such as echocardiography, around 30 positive cases were identified, providing timely diagnoses and support for subsequent treatment.

Environmental Performance Indicators [1]

	Data			Unit
	2025	2024	2023	
Air emissions				
Nitrogen oxides	1,982.7	2,552.2	1,598.0	Kilograms
Sulphur oxides	456.2	580.5	365.4	Kilograms
Respiratory suspended particles	193.9	249.8	156.6	Kilograms
GHG emissions				
Scope 1	1,858.3	2,352.8	1,528.0	Tonnes of CO_2-e
Scope 2	5,981.5	5,686.8	7,588.1	Tonnes of CO_2-e
Total GHG emissions (Scope 1 and Scope 2)	7,839.8	8,039.6	9,116.0	Tonnes of CO_2-e
GHG intensity (Scope 1 and Scope 2, per floor area in square metres)	0.2	0.2	0.2	Tonnes of CO_2-e/m^2
Scope 3[2]				
Waste treatment	205.3	288.3	/	Tonnes of CO_2-e
Business travel	752.1	641.8	/	Tonnes of CO_2-e
Downstream leased properties	2,929.6	/	/	Tonnes of CO_2-e
Hazardous waste				
Total amount of hazardous waste	53.4	52.3	39.0	Tonnes
Intensity of hazardous waste (per floor area in square metres)	0.001	0.001	0.001	Tonnes/m^2
Non-hazardous waste				
Total amount of non-hazardous waste	107.0	419.1	232.4	Tonnes
Intensity of non-hazardous waste (per floor area in square metres)	0.003	0.009	0.005	Tonnes/m^2
Energy consumption				
Gasoline	175.2	184.9	199.0	MWh
Diesel	69.0	79.7	35.4	MWh
Natural gas	8,667.3	11,031.9	6,941.0	MWh
Purchased electricity	14,798.3	13,145.6	14,395.9	MWh
Total energy consumption	23,709.8	24,442.1	21,571.3	MWh
Energy intensity (per floor area in square metres)	0.6	0.5	0.4	MWh/m^2

	Data			Unit
	2025	2024	2023	
Water consumption				
Total water consumption	147,627.3	85,406.0	126,666.3	Tonnes
Water consumption intensity (per floor area in square metres)	3.70	1.8	2.6	Tonnes/m^2
Packaging materials used for finished products				
Total amount of packaging materials	16.1	16.0	16.3	Tonnes
Intensity of packaging materials (per floor area in square metres)	0.4	0.3	0.3	Kilograms/m^2
Intensity of packaging materials (calculated by production volume)	0.04	0.05	0.04	Kilograms/ number of products

Note:

1. Environmental figures are calculated with reference to *How to prepare an ESG Report - Appendix 2: Reporting Guidance on Environmental KPIs* published by the Stock Exchange.

2. Scope 3 GHG emissions have been clearly categorised in accordance with the Greenhouse Gas Protocol, primarily covering emissions related to waste disposal, business travel, and downstream leased properties. Regarding other categories of Scope 3 emission sources, the Group will continuously enhance its data acquisition capabilities, gradually incorporate them into the statistical system, and employ established accounting methods to further disclose relevant information.

Social Performance Indicators

		2025		2024	
		Number	%	Number	%
Number of employees					
Total number of employees		1,202	N/A	1,324	N/A
Gender	Male	612	50.9%	687	51.9%
	Female	590	49.1%	637	48.1%
Grade	Chief executives	5	0.4%	3	0.2%
	Senior executives	18	1.5%	22	1.7%
	Middle management	128	10.7%	129	9.7%
	General staff	1,051	87.4%	1,170	88.4%
Age	Under 30	336	28.0%	435	32.8%
	30-40	692	57.5%	707	53.4%
	41-50	149	12.4%	152	11.5%
	Over 50	25	2.1%	30	2.3%
Area	Shenzhen	608	50.6%	888	67.1%
	Dongguan	534	44.4%	386	29.1%
	Overseas	60	5.0%	50	3.8%
Employment type	Full-time	1,186	98.7%	1,296	97.9%
	Contract	9	0.7%	7	0.5%
	Apprentices and interns	7	0.6%	21	1.6%

		2025		2024	
		Number	%	Number	%
Employee turnover					
Total number of turnovers		326	27.1%	363	27.4%
Gender	Male	184	30.1%	199	29.0%
	Female	142	24.1%	164	25.7%
Grade	Chief executives	0	0.0%	0	0.0%
	Senior executives	1	5.6%	0	0.0%
	Middle management	18	14.1%	9	7.0%
	General staff	307	29.2%	354	30.3%
Age	Under 30	166	49.4%	154	35.4%
	30-40	131	18.9%	185	26.2%
	41-50	23	15.4%	22	14.5%
	Over 50	6	24.0%	2	6.7%
Area	Chinese Mainland	322	28.2%	351	27.6%
	Overseas	4	6.7%	12	24.0%
New employees					
Total number of new employees		210	17.5%	309	23.3%
Gender	Male	119	19.4%	135	19.7%
	Female	91	15.4%	174	27.3%
Grade	Chief executives	0	0.0%	0	0.0%
	Senior executives	2	11.1%	0	0.0%
	Middle management	15	11.7%	18	14.0%
	General staff	193	18.4%	291	24.9%
Age	Under 30	131	39.0%	188	43.2%
	30-40	71	10.3%	109	15.4%
	41-50	8	5.4%	11	7.2%
	Over 50	0	0.0%	1	3.3%
Area	Chinese Mainland	196	17.2%	296	23.2%
	Overseas	14	23.3%	13	26.0%

		2025		2024	
		Number	%	Number	%
Performance in development and training					
Total number of trained employees		1,142	95.0%	1,324	100.0%
Total training hours of employees		32,060.3	N/A	50,040.6	N/A
Average training hours per employee		28.1	N/A	37.8	N/A
Number of trained employees					
Gender	Male	565	92.3%	687	100.0%
	Female	577	97.8%	637	100.0%
Grade	Chief executives	5	100.0%	3	100.0%
	Senior executives	17	94.4%	22	100.0%
	Middle management	92	71.9%	129	100.0%
	General staff	1,028	97.8%	1,170	100.0%
Average training hours					
Gender	Male	28.07	N/A	37.5	N/A
	Female	28.08	N/A	38.1	N/A
Grade	Chief executives	19.24	N/A	52.5	N/A
	Senior executives	28.29	N/A	47.5	N/A
	Middle management	28.58	N/A	34.6	N/A
	General staff	28.07	N/A	37.9	N/A

Supply chain management performance	Number of suppliers	Materials/services provided
Chinese Mainland	184	Polymer materials, metal materials, tooling, production auxiliary materials and outsourcing, etc.
Others, such as the U.S., Germany, Singapore, Switzerland	23	Polymer tubing and metal raw materials, etc.

Occupational health and safety performance	Total		
	2025	2024	2023
Number of work-related fatalities	0	0	0
Percentage of work-related fatalities	0%	0%	0%
Number of work-related injuries	0	0	0
Number of working days lost due to work injury	0	0	0
Number of absent days	0	0	0

Performance in product responsibility	2025	2024	2023
Number of products subject to recalls for health and safety reasons	0	0	0
Percentage of products subject to recalls for health and safety reasons	0%	0%	0%
Number of products and service-related complaints received	76	118	124
Percentage of timely addressed of products and service-related complaints received	100.0%	100.0%	96.8%

Performance in anti-corruption	2025	2024	2023
Number of concluded cases regarding corrupt practice brought against LifeTech or its employees	0	0	0
Total anti-corruption training hours provided for directors (hours)	5	2	2
Average anti-corruption training hours provided for employees (hours)	0.3	0.4	0.4

Part D: "Comply or Explain" provisions

Subject areas	Content	Chapter index and remarks
A1 Emissions		
General disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	Energy Efficiency and Carbon Emissions Management Gas Emissions Management Water Resource Management Waste and Recycled Materials Management
A1.1	The types of emissions and respective emissions data.	Gas Emissions Management KPI Overview
A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Waste and Recycled Materials Management KPI Overview
A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Waste and Recycled Materials Management KPI Overview
A1.5	Description of emissions target(s); and steps taken to achieve them.	Energy Efficiency and Carbon Emissions Management
A1.6	Description of how hazardous and non-hazardous wastes are handled; steps taken to achieve them; and description of reduction target(s) set.	Energy Efficiency and Carbon Emissions Management Waste and Recycled Materials Management

Subject areas	Content	Chapter index and remarks
A2 Use of resources		
General disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	Energy Efficiency and Carbon Emissions Management
A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	KPI Overview
A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	KPI Overview
A2.3	Description of energy use efficiency target(s) and steps taken to achieve them.	Energy Efficiency and Carbon Emissions Management
A2.4	Description of whether there is any issue in sourcing water that is fit for purpose; water efficiency target(s) set; and steps taken to achieve them.	Water Resource Management
A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	Management of Packaging Materials KPI Overview
A3 Environment and natural resources		
General disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	Environment and Natural Resources
A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	Environment and Natural Resources

Subject areas	Content	Chapter index and remarks
B1 Employment		
General disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Employee Benefits and Welfare
B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	KPI Overview
B1.2	Employee turnover rate by gender, age group and geographical region.	KPI Overview
B2 Health and safety		
General disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Health and Safety
B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	KPI Overview
B2.2	Lost days due to work injury.	KPI Overview
B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	Health and Safety
B3 Development and training		
General disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Talent Management and Development
B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	KPI Overview
B3.2	The average training hours completed per employee by gender and employee category.	KPI Overview

Subject areas	Content	Chapter index and remarks
B4 Labour standards		
General disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	Employee Benefits and Welfare
B4.1	Description of measures to review employment practices to avoid child and forced labour.	Employee Benefits and Welfare
B4.2	Description of steps taken to eliminate such practices when discovered.	Employee Benefits and Welfare
B5 Supply chain management		
General disclosure	Policies on managing environmental and social risks of the supply chain.	Supply Chain Management
B5.1	Number of suppliers by geographical region.	Supply Chain Management
B5.2	Description of practices relating to engaging suppliers, and how they are implemented and monitored.	Supply Chain Management
B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	Supply Chain Management
B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	Supply Chain Management

Subject areas	Content	Chapter index and remarks
B6 Product responsibility		
General disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	Product Quality and Safety Product Responsibility Customer Service Information Security Protection of Intellectual Property Rights
B6.1	Percentage of total products sold or shipped subject to recalls for health and safety reasons.	KPI Overview
B6.2	Number of products and service-related complaints received and how they are dealt with.	Customer Service
B6.3	Description of practices relating to observing and protecting intellectual property rights.	Protection of Intellectual Property Rights
B6.4	Description of quality assurance process and recall procedures.	Product Quality and Safety Customer Service
B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	Information Security
B7 Anti-corruption		
General disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to prevention of bribery, extortion, fraud and money laundering.	Corporate Governance and Risk Management Anti-corruption, Anti-bribery and Anti-competition
B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the Reporting Period and the outcomes of the cases.	KPI Overview
B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	Corporate Governance and Risk Management Anti-corruption, Anti-bribery and Anti-competition Whistle-blowing Procedures
B7.3	Description of anti-corruption training provided to directors and staff.	Corporate Governance and Risk Management Anti-corruption, Anti-bribery and Anti-competition

Subject areas	Content	Chapter index and remarks
B8 Community investment		
General disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Focusing on Social Needs and Engaging in Public Welfare Initiatives
B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	Focusing on Social Needs and Engaging in Public Welfare Initiatives
B8.2	Resources contributed (e.g. money or time) to the focus area.	Focusing on Social Needs and Engaging in Public Welfare Initiatives

Part D: Climate-related Disclosures

Subject areas	Description	Chapter index and remarks
Governance	19(a) Information about the governance body(s) (which can include the Board, Committee or equivalent governance body) or individual(s) responsible for overseeing climate-related risks and opportunities. Specifically, an issuer must identify the relevant body(s) or individual(s) and disclose the following information: (i) how the body(s) or individual(s) determines whether they have or will have appropriate skills and competencies to oversee strategies to respond to climate-related risks and opportunities; (ii) how and how often the body(s) or individual(s) is informed about climate-related risks and opportunities; (iii) how the body(s) or individual(s) considers climate-related risks and opportunities when overseeing the issuer's strategy, its decisions on major transactions, and its risk management processes and related policies, including whether the body(s) or individual(s) has considered trade-offs associated with those risks and opportunities; and (iv) how the body(s) or individual(s) oversees the setting of targets related to climate-related risks and opportunities, and monitors progress towards them, including whether and how related performance indicators are included in remuneration policies.	Responding to Climate Change

Subject areas		Description	Chapter index and remarks
	19(b)	Management's role in the governance processes, controls and procedures used to monitor, manage and oversee climate-related risks and opportunities, including the following information: (i) whether the role is delegated to a specific management-level position or management-level committee and how oversight is exercised over that position or committee; and (ii) whether management uses controls and procedures to support the oversight of climate-related risks and opportunities; and, if so, how these controls and procedures are integrated with other internal functional departments.	Responding to Climate Change
Strategy	20	An issuer must disclose information that enables others to understand the climate-related risks and opportunities that could reasonably be expected to affect its cash flows, access to finance or cost of capital over the short, medium or long term. Specifically, the issuer must: (a) describe the climate-related risks and opportunities that could reasonably be expected to affect the issuer's cash flows, access to finance or cost of capital over the short, medium or long term; (b) explain, for each climate-related risk the issuer has identified, whether the issuer considers the risk to be a climate-related physical risk or climate-related transition risk; (c) specify, for each climate-related risk and opportunity the issuer has identified, the time horizon (short, medium or long term) over which it could reasonably be expected to affect the issuer; and (d) explain how the issuer defines the short, medium and long term, and how these definitions are linked to the planning horizons used for strategic decision-making.	Responding to Climate Change
	21	An issuer must disclose information that enables others to understand the current and anticipated effects of climate-related risks and opportunities on its business model and value chain. Specifically, the issuer must: (a) describe the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain; (b) describe where climate-related risks and opportunities are concentrated in the issuer's business model and value chain (for example, geographical areas, facilities and types of assets).	Responding to Climate Change

Subject areas	Description	Chapter index and remarks
	22(a) An issuer must disclose information that enables others to understand the effects of climate-related risks and opportunities on its strategy and decision-making. Specifically, an issuer must disclose information about how the issuer has responded and plans to respond to climate-related risks and opportunities in its strategy and decision-making, including how the issuer plans to achieve any climate-related targets it has set and any targets it is required to meet by law or regulation. Specifically, an issuer must disclose the following information: (i) current and anticipated changes to the issuer's business model (including resource allocation) in response to climate-related risks and opportunities; (ii) any adaptation or mitigation efforts (direct or indirect) that have been or are anticipated to be undertaken; (iii) any climate-related transition plan of the issuer (including information about key assumptions used in developing the transition plan, and dependencies on which the plan relies), or an appropriate negative statement if the issuer does not have such a plan; (iv) how the issuer plans to achieve any climate-related targets described in paragraphs 37 to 40 (including any GHG emissions targets (if any)).	Responding to Climate Change
	22(b) An issuer must disclose information about how the issuer currently resources, and plans to resource, the activities disclosed in accordance with paragraph 22(a).	Responding to Climate Change
	23. An issuer must disclose the progress of plans disclosed in accordance with paragraph 22(a) in previous reporting periods.	Indicator and Goals
	24 An issuer must disclose the following qualitative and quantitative information: (a) how climate-related risks and opportunities have affected the issuer's financial position, financial performance and cash flows for the reporting period; and (b) information about the climate-related risks and opportunities identified in paragraph 24(a) for which there is a significant risk of a material adjustment to the carrying amounts of assets and liabilities in the related financial statements within the next reporting year.	Qualitative Information: Responding to Climate Change Quantitative Information: Implementation of Financial Effects Relief

Subject areas	Description	Chapter index and remarks
	25(a) An issuer must disclose the following qualitative and quantitative information: how the issuer expects its financial performance to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities, and taking into consideration the following items: (i) its investment and disposal plans; and (ii) its planned sources of funding to implement its strategy.	Qualitative Information: Responding to Climate Change Quantitative Information: Implementation of Financial Effects Relief
	25(b) An issuer must disclose the following qualitative and quantitative information: how the issuer expects its financial performance and cash flows to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities.	Implementation of Financial Effects Relief
	26(a) Taking into consideration the issuer's identified climate-related risks and opportunities, the issuer must disclose information that enables others to understand the resilience of the issuer's strategy and business model to climate-related changes, developments or uncertainties. The issuer must use climate-related scenario analysis to assess its climate resilience, using an approach that is commensurate with its circumstances. In providing quantitative information, the issuer may disclose a single amount or a range. Specifically, the issuer must disclose the issuer's assessment of its climate resilience as at the reporting date, which enables an understanding of: (i) the implications of the issuer's analysis for its strategy and business model (if any), including how the issuer would need to respond to the effects identified in the climate-related scenario analysis; (ii) the scope of significant uncertainties considered in the issuer's assessment of its climate resilience; and (iii) the issuer's capacity to adjust its strategy and business model over the short, medium and long term to climate developments.	Implementation of Capabilities Relief

Subject areas	Description	Chapter index and remarks
	26(b) An issuer must disclose how and when the climate-related scenario analysis was carried out, including: (i) the inputs used, including: 1) climate-related scenarios the issuer used in the analysis and their sources; 2) whether the analysis included a diverse range of climate-related scenarios; 3) whether the climate-related scenarios used in the analysis are associated with climate-related transition risks or climate-related physical risks; 4) whether the issuer used, among its scenarios, a scenario aligned with the latest international agreement on climate change; 5) why the issuer considers the selected climate-related scenarios to be relevant to assessing its resilience to climate-related changes, developments or uncertainties; 6) the time horizons the issuer used in the analysis; and 7) the scope of operations covered in the issuer's analysis (for example, the operating locations and business units covered in the analysis); (ii) the key assumptions the issuer made in the analysis; and (iii) the reporting period in which the climate-related scenario analysis was carried out.	Implementation of Capabilities Relief
Risk management	27(a) An issuer must disclose the following information: the processes and related policies the issuer uses to identify, assess, prioritise and monitor climate-related risks, including information about: (i) the inputs and parameters the issuer uses (for example, data sources and the scope of operations covered in the processes); (ii) whether and how the issuer uses climate-related scenario analysis to identify climate-related risks; (iii) how the issuer assesses the nature, likelihood and magnitude of the effects of those risks (for example, whether the issuer considers qualitative factors, quantitative thresholds or other criteria used); (iv) whether and how the issuer prioritises climate-related risks relative to other types of risks; (v) how the issuer monitors its climate-related risks; and (vi) whether and how the issuer has changed the processes it uses compared with the previous reporting period.	Responding to Climate Change

Subject areas	Description	Chapter index and remarks
	27(b) the processes the issuer uses to identify, assess, prioritise and monitor climate-related opportunities (including information about whether and how the issuer uses climate-related scenario analysis to confirm climate-related opportunities).	Responding to Climate Change
	27(c) how and to what extent the processes for identifying, assessing, prioritising and monitoring climate-related risks and opportunities are integrated into the issuer's overall risk management processes.	Responding to Climate Change
Indicator and goals	28. An issuer must disclose its absolute gross GHG emissions during the reporting period (in tonnes of CO_2-e), classified as: (a) Scope 1 GHG emissions; (b) Scope 2 GHG emissions; and (c) Scope 3 GHG emissions.	KPI Overview
	29 An issuer must: (a) measure its GHG emissions in accordance with the *Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (2004)* unless otherwise required by a jurisdictional authority or another exchange on which the issuer is listed; (b) disclose the methods it uses to measure GHG emissions, including: (i) the measurement methods, inputs and assumptions the issuer uses to measure its GHG emissions; (ii) why the issuer has chosen the measurement methods, inputs and assumptions to measure GHG emissions; and (iii) any changes the issuer made to the measurement methods, inputs and assumptions during the reporting period and the reasons for those changes; (c) for Scope 2 GHG emissions disclosed in accordance with paragraph 28(b), disclose its location-based Scope 2 GHG emissions, and provide information about any contractual instruments that are necessary to understand such emissions; and (d) for Scope 3 GHG emissions disclosed in accordance with paragraph 28(c), disclose the categories included within the issuer's measure of Scope 3 GHG emissions, in accordance with the Scope 3 categories described in the *Greenhouse Gas Protocol: Corporate Value Chain (Scope 3) Accounting and Reporting Standard (2011)*.	KPI Overview

Subject areas	Description	Chapter index and remarks
	30. An issuer must disclose the amount and percentage of assets or business activities vulnerable to climate-related transition risks.	Implementation of Reasonable Information Relief
	31. An issuer must disclose the amount and percentage of assets or business activities vulnerable to climate-related physical risks.	Implementation of Reasonable Information Relief
	32. An issuer must disclose the amount and percentage of assets or business activities involving climate-related opportunities.	Implementation of Reasonable Information Relief
	33. An issuer must disclose the amount of capital expenditure, financing or investment used for climate-related risks and opportunities.	Responding to Climate Change
	34. An issuer must disclose: (a) whether and how the issuer applies carbon pricing in decision-making (for example, investment decisions, transfer pricing and scenario analysis); and (b) the price for each metric tonne of GHG emissions that the issuer uses to assess the costs of its GHG emissions; or an appropriate negative statement confirming that the issuer does not apply carbon pricing in decision-making.	During the Reporting Period, the Group has not yet implemented carbon pricing.
	35. An issuer must disclose whether and how climate-related considerations are factored into its remuneration policy, or provide an appropriate negative statement. This may form part of the disclosures made pursuant to paragraph 19(a)(iv).	During the Reporting Period, the Group has not yet incorporated climate-related factors into its remuneration policy.

Subject areas	Description	Chapter index and remarks
	36. The Exchange encourages an issuer to disclose industry-specific indicators that are associated with one or more particular business models and activities or industry indicators that are associated with common features of participation in the relevant industry. In determining which industry-based indicators to disclose, the Exchange encourages the issuer to refer to, and consider the applicability of, the industry-based indicators that are associated with disclosure topics described in the Industry-based Guidance on Implementing *IFRS S2 and Industry Disclosure* requirements provided by other international environmental, social and governance reporting frameworks.	Responding to Climate Change
	37. An issuer must disclose (a) the qualitative and quantitative climate-related targets it has set to monitor progress towards achieving its strategic goals; and (b) any targets it is required to meet by law or regulation, including any GHG emissions targets. For each target, an issuer must disclose: (a) the indicator used to set the target; (b) the objective of the target (for example, mitigation, adaptation or science-based initiatives); (c) the scope to which the target applies (for example, whether the target applies to the issuer's entire group or a part (such as only a specific business unit or geographical region)); (d) the period over which the target applies; (e) the base period from which the progress is measured; (f) any milestones or interim targets (if any); (g) if the target is quantitative, whether it is an absolute target or an intensity target; and (h) how the latest international agreement on climate change, including jurisdictional commitments that arise from that agreement, has informed the issuer's target.	Responding to Climate Change
	38. An issuer must disclose its approach to setting and reviewing each target, and how it monitors progress towards reaching each target, including: (a) whether the target and the methodology for setting the target have been validated by a third party; (b) the issuer's processes for reviewing the target; (c) the indicators used to monitor progress towards the target; and (d) any revisions to the target and an explanation for those revisions.	Responding to Climate Change

Subject areas	Description	Chapter index and remarks
	39. An issuer must disclose information about its performance against each climate-related target and an analysis of trends or changes in the issuer's performance.	Responding to Climate Change
	40. For each GHG emissions target disclosed under paragraphs 37 to 39, an issuer must disclose: (a) greenhouse gases covered by the target; (b) whether Scope 1, Scope 2 or Scope 3 GHG emissions are covered by the target; (c) whether the target is a gross GHG emissions target or net GHG emissions target. If the target is a net GHG emissions target, the issuer must also disclose a related gross GHG emissions target; (d) whether the target was derived using a sectoral decarbonisation approach; and (e) the issuer's planned use of carbon credits to offset GHG emissions to achieve any net GHG emissions targets. Regarding the plan to use carbon credits, the issuer must disclose: (i) the extent and manner of reliance on the use of carbon credits to achieve any net GHG emissions targets; (ii) which third-party schemes will verify or certify the carbon credits; (iii) the type of carbon credits, including whether the relevant offset is nature-based or technology-based carbon removal, and whether the relevant offset is achieved through carbon reduction or carbon removal; and (iv) any other material factors necessary for understanding the credibility and integrity of the carbon credits the issuer plans to use (for example, assumptions regarding the effectiveness of the carbon offsets).	Responding to Climate Change During the reporting period, the Group had not adopted or planned to adopt carbon credits to offset greenhouse gas emissions to achieve any net greenhouse gas emission targets.
	41. In preparing disclosures to comply with the requirements of paragraphs 21 to 26 and 37 to 38, the issuer must refer to and consider the applicability of (i) cross-industry indicators (see paragraphs 28 to 35) and (ii) industry-specific indicators (see paragraph 36).	Implementation of Reasonable Information Relief